

CHAPTER 22

Respiratory System Infections



Figure 22.1 Aerosols produced by sneezing, coughing, or even just speaking are an important mechanism for respiratory pathogen transmission. Simple actions, like covering your mouth when coughing or sneezing, can reduce the spread of these microbes. (credit: modification of work by Centers for Disease Control and Prevention)

Chapter Outline

[22.1 Anatomy and Normal Microbiota of the Respiratory Tract](#)

[22.2 Bacterial Infections of the Respiratory Tract](#)

[22.3 Viral Infections of the Respiratory Tract](#)

[22.4 Respiratory Mycoses](#)

INTRODUCTION The respiratory tract is one of the main portals of entry into the human body for microbial pathogens. On average, a human takes about 20,000 breaths each day. This roughly corresponds to 10,000 liters, or 10 cubic meters, of air. Suspended within this volume of air are millions of microbes of terrestrial, animal, and human origin—including many potential pathogens. A few of these pathogens will cause relatively mild infections like sore throats and colds. Others, however, are less benign. According to the World Health Organization, respiratory tract infections such as tuberculosis, influenza, and pneumonia were responsible for more than 4 million deaths worldwide in 2012.¹

At one time, it was thought that antimicrobial drugs and preventive vaccines might hold respiratory infections in check in the developed world, but recent developments suggest otherwise. The rise of multiple-antibiotic resistance in organisms like *Mycobacterium tuberculosis* has rendered many of our modern drugs ineffective.

1 World Health Organization. “The Top Ten Causes of Death.” May 2014. <http://www.who.int/mediacentre/factsheets/fs310/en/>

In addition, there has been a recent resurgence in diseases like whooping cough and measles, once-common childhood illnesses made rare by effective vaccines. Despite advances in medicine and public health programs, it is likely that respiratory pathogens will remain formidable adversaries for the foreseeable future.

22.1 Anatomy and Normal Microbiota of the Respiratory Tract

Learning Objectives

By the end of this section, you will be able to:

- Describe the major anatomical features of the upper and lower respiratory tract
- Describe the normal microbiota of the upper and lower respiratory tracts
- Explain how microorganisms overcome defenses of upper and lower respiratory-tract membranes to cause infection
- Explain how microbes and the respiratory system interact and modify each other in healthy individuals and during an infection

Clinical Focus

Part 1

John, a 65-year-old man with asthma and type 2 diabetes, works as a sales associate at a local home improvement store. Recently, he began to feel quite ill and made an appointment with his family physician. At the clinic, John reported experiencing headache, chest pain, coughing, and shortness of breath. Over the past day, he had also experienced some nausea and diarrhea. A nurse took his temperature and found that he was running a fever of 40 °C (104 °F).

John suggested that he must have a case of influenza (flu), and regretted that he had put off getting his flu vaccine this year. After listening to John's breathing through a stethoscope, the physician ordered a chest radiography and collected blood, urine, and sputum samples.

- Based on this information, what factors may have contributed to John's illness?

Jump to the [next](#) Clinical Focus box.

The primary function of the respiratory tract is to exchange gases (oxygen and carbon dioxide) for metabolism. However, inhalation and exhalation (particularly when forceful) can also serve as a vehicle of transmission for pathogens between individuals.

Anatomy of the Upper Respiratory System

The respiratory system can be conceptually divided into upper and lower regions at the point of the **epiglottis**, the structure that seals off the lower respiratory system from the **pharynx** during swallowing ([Figure 22.2](#)). The upper respiratory system is in direct contact with the external environment. The nares (or nostrils) are the external openings of the nose that lead back into the **nasal cavity**, a large air-filled space behind the nares. These anatomical sites constitute the primary opening and first section of the respiratory tract, respectively. The nasal cavity is lined with hairs that trap large particles, like dust and pollen, and prevent their access to deeper tissues. The nasal cavity is also lined with a mucous membrane and Bowman's glands that produce mucus to help trap particles and microorganisms for removal. The nasal cavity is connected to several other air-filled spaces. The sinuses, a set of four, paired small cavities in the skull, communicate with the nasal cavity through a series of small openings. The **nasopharynx** is part of the upper throat extending from the posterior nasal cavity. The nasopharynx carries air inhaled through the nose. The middle ear is connected to the nasopharynx through the **eustachian tube**. The middle ear is separated from the outer ear by the **tympanic membrane**, or ear drum. And finally, the lacrimal glands drain to the nasal cavity through the **nasolacrimal ducts** (tear ducts). The open connections between these sites allow microorganisms to move from the nasal cavity to the sinuses, middle ears (and back), and down into the lower respiratory tract from the nasopharynx.

The oral cavity is a secondary opening for the respiratory tract. The oral and nasal cavities connect through the

fauces to the pharynx, or throat. The pharynx can be divided into three regions: the nasopharynx, the **oropharynx**, and the **laryngopharynx**. Air inhaled through the mouth does not pass through the nasopharynx; it proceeds first through the oropharynx and then through the laryngopharynx. The **palatine tonsils**, which consist of lymphoid tissue, are located within the oropharynx. The laryngopharynx, the last portion of the pharynx, connects to the **larynx**, which contains the vocal fold (Figure 22.2).




Figure 22.2 (a) The ear is connected to the upper respiratory tract by the eustachian tube, which opens to the nasopharynx. (b) The structures of the upper respiratory tract.

✓ CHECK YOUR UNDERSTANDING

- Identify the sequence of anatomical structures through which microbes would pass on their way from the nares to the larynx.
- What two anatomical points do the eustachian tubes connect?

Anatomy of the Lower Respiratory System

The lower respiratory system begins below the epiglottis in the larynx or voice box (Figure 22.3). The **trachea**, or windpipe, is a cartilaginous tube extending from the larynx that provides an unobstructed path for air to reach the lungs. The trachea bifurcates into the left and right **bronchi** as it reaches the lungs. These paths branch repeatedly to form smaller and more extensive networks of tubes, the **bronchioles**. The terminal bronchioles formed in this tree-like network end in cul-de-sacs called the **alveoli**. These structures are surrounded by capillary networks and are the site of gas exchange in the respiratory system. Human lungs contain on the order of 400,000,000 alveoli. The outer surface of the lungs is protected with a double-layered pleural membrane. This structure protects the lungs and provides lubrication to permit the lungs to move easily during respiration.




Figure 22.3 The structures of the lower respiratory tract are identified in this illustration. (credit: modification of work by National Cancer Institute)

Defenses of the Respiratory System

The inner lining of the respiratory system consists of mucous membranes ([Figure 22.4](#)) and is protected by multiple immune defenses. The goblet cells within the respiratory epithelium secrete a layer of sticky mucus. The viscosity and acidity of this secretion inhibits microbial attachment to the underlying cells. In addition, the respiratory tract contains ciliated epithelial cells. The beating cilia dislodge and propel the mucus, and any trapped microbes, upward to the epiglottis, where they will be swallowed. Elimination of microbes in this manner is referred to as the mucociliary escalator effect and is an important mechanism that prevents inhaled microorganisms from migrating further into the lower respiratory tract.




Figure 22.4 This micrograph shows the structure of the mucous membrane of the respiratory tract. (credit: modification of micrograph provided by the Regents of University of Michigan Medical School © 2012)

The upper respiratory system is under constant surveillance by mucosa-associated lymphoid tissue (MALT), including the adenoids and tonsils. Other mucosal defenses include secreted antibodies (IgA), lysozyme, surfactant, and antimicrobial peptides called defensins. Meanwhile, the lower respiratory tract is protected by alveolar macrophages. These phagocytes efficiently kill any microbes that manage to evade the other defenses. The combined action of these factors renders the lower respiratory tract nearly devoid of colonized microbes.

✓ CHECK YOUR UNDERSTANDING

- Identify the sequence of anatomical structures through which microbes would pass on their way from the larynx to the alveoli.
- Name some defenses of the respiratory system that protect against microbial infection.

Normal Microbiota of the Respiratory System

The upper respiratory tract contains an abundant and diverse microbiota. The nasal passages and sinuses are primarily colonized by members of the Firmicutes, Actinobacteria, and Proteobacteria. The most common bacteria identified include *Staphylococcus epidermidis*, viridans group streptococci (VGS), *Corynebacterium* spp. (diphtheroids), *Propionibacterium* spp., and *Haemophilus* spp. The oropharynx includes many of the same isolates as the nose and sinuses, with the addition of variable numbers of bacteria like species of *Prevotella*, *Fusobacterium*, *Moraxella*, and *Eikenella*, as well as some *Candida* fungal isolates. In addition, many healthy humans asymptotically carry potential pathogens in the upper respiratory tract. As much as 20% of the population carry *Staphylococcus aureus* in their nostrils.² The pharynx, too, can be colonized with pathogenic strains of *Streptococcus*, *Haemophilus*, and *Neisseria*.

The lower respiratory tract, by contrast, is scantily populated with microbes. Of the organisms identified in the lower respiratory tract, species of *Pseudomonas*, *Streptococcus*, *Prevotella*, *Fusobacterium*, and *Veillonella* are the most common. It is not clear at this time if these small populations of bacteria constitute a normal microbiota or if they are transients.

2 J. Kluytmans et al. "Nasal Carriage of *Staphylococcus aureus*: Epidemiology, Underlying Mechanisms, and Associated Risks." *Clinical Microbiology Reviews* 10 no. 3 (1997):505–520.

Many members of the respiratory system's normal microbiota are opportunistic pathogens. To proliferate and cause host damage, they first must overcome the immune defenses of respiratory tissues. Many mucosal pathogens produce virulence factors such as adhesins that mediate attachment to host epithelial cells, or polysaccharide capsules that allow microbes to evade phagocytosis. The endotoxins of gram-negative bacteria can stimulate a strong inflammatory response that damages respiratory cells. Other pathogens produce exotoxins, and still others have the ability to survive within the host cells. Once an infection of the respiratory tract is established, it tends to impair the mucociliary escalator, limiting the body's ability to expel the invading microbes, thus making it easier for pathogens to multiply and spread.

Vaccines have been developed for many of the most serious bacterial and viral pathogens. Several of the most important respiratory pathogens and their vaccines, if available, are summarized in [Table 22.1](#). Components of these vaccines will be explained later in the chapter.

Some Important Respiratory Diseases and Vaccines

Disease	Pathogen	Available Vaccine(s) ³
Chickenpox/shingles	Varicella-zoster virus	Varicella (chickenpox) vaccine, herpes zoster (shingles) vaccine
Common cold	Rhinovirus	None
Diphtheria	<i>Corynebacterium diphtheriae</i>	DtaP, Tdap, DT,Td, DTP
Epiglottitis, otitis media	<i>Haemophilus influenzae</i>	Hib
Influenza	Influenza viruses	Inactivated, FluMist
Measles	Measles virus	MMR
Pertussis	<i>Bordetella pertussis</i>	DTaP, Tdap
Pneumonia	<i>Streptococcus pneumoniae</i>	Pneumococcal conjugate vaccine (PCV13), pneumococcal polysaccharide vaccine (PPSV23)
Rubella (German measles)	Rubella virus	MMR
Severe acute respiratory syndrome (SARS)	SARS-associated coronavirus (SARS-CoV)	None
Tuberculosis	<i>Mycobacterium tuberculosis</i>	BCG

Table 22.1

³ Full names of vaccines listed in table: *Haemophilus influenzae* type B (Hib); Diphtheria, tetanus, and acellular pertussis (DtaP); tetanus, diphtheria, and acellular pertussis (Tdap); diphtheria and tetanus (DT); tetanus and diphtheria (Td); diphtheria, pertussis, and tetanus (DTP); Bacillus Calmette-Guérin; Measles, mumps, rubella (MMR)

✓ CHECK YOUR UNDERSTANDING

- What are some pathogenic bacteria that are part of the normal microbiota of the respiratory tract?
- What virulence factors are used by pathogens to overcome the immune protection of the respiratory tract?

Signs and Symptoms of Respiratory Infection

Microbial diseases of the respiratory system typically result in an acute inflammatory response. These infections can be grouped by the location affected and have names ending in “itis”, which literally means *inflammation of*. For instance, **rhinitis** is an inflammation of the nasal cavities, often characteristic of the common cold. Rhinitis may also be associated with hay fever allergies or other irritants. Inflammation of the sinuses is called **sinusitis** inflammation of the ear is called **otitis**. Otitis media is an inflammation of the middle ear. A variety of microbes can cause **pharyngitis**, commonly known as a sore throat. An inflammation of the larynx is called **laryngitis**. The resulting inflammation may interfere with vocal cord function, causing voice loss. When tonsils are inflamed, it is called **tonsillitis**. Chronic cases of tonsillitis may be treated surgically with tonsillectomy. More rarely, the epiglottis can be infected, a condition called **epiglottitis**. In the lower respiratory system, the inflammation of the bronchial tubes results in **bronchitis**. Most serious of all is **pneumonia**, in which the alveoli in the lungs are infected and become inflamed. Pus and edema accumulate and fill the alveoli with fluids (called consolidations). This reduces the lungs’ ability to exchange gases and often results in a productive cough expelling phlegm and mucus. Cases of pneumonia can range from mild to life-threatening, and remain an important cause of mortality in the very young and very old.

✓ CHECK YOUR UNDERSTANDING

- Describe the typical symptoms of rhinitis, sinusitis, pharyngitis, and laryngitis.

Case in Point

Smoking-Associated Pneumonia

Camila is a 22-year-old student who has been a chronic smoker for 5 years. Recently, she developed a persistent cough that has not responded to over-the-counter treatments. Her doctor ordered a chest radiograph to investigate. The radiological results were consistent with pneumonia. In addition, *Streptococcus pneumoniae* was isolated from Camila’s sputum.

Smokers are at a greater risk of developing pneumonia than the general population. Several components of tobacco smoke have been demonstrated to impair the lungs’ immune defenses. These effects include disrupting the function of the ciliated epithelial cells, inhibiting phagocytosis, and blocking the action of antimicrobial peptides. Together, these lead to a dysfunction of the mucociliary escalator effect. The organisms trapped in the mucus are therefore able to colonize the lungs and cause infections rather than being expelled or swallowed.

22.2 Bacterial Infections of the Respiratory Tract

Learning Objectives

By the end of this section, you will be able to:

- Identify the most common bacteria that can cause infections of the upper and lower respiratory tract
- Compare the major characteristics of specific bacterial diseases of the respiratory tract

The respiratory tract can be infected by a variety of bacteria, both gram positive and gram negative. Although the diseases that they cause may range from mild to severe, in most cases, the microbes remain localized within the respiratory system. Fortunately, most of these infections also respond well to antibiotic therapy.

Streptococcal Infections

A common upper respiratory infection, **streptococcal pharyngitis (strep throat)** is caused by *Streptococcus pyogenes*. This gram-positive bacterium appears as chains of cocci, as seen in [Figure 22.5](#). Rebecca Lancefield serologically classified streptococci in the 1930s using carbohydrate antigens from the bacterial cell walls. *S. pyogenes* is the sole member of the Lancefield group A streptococci and is often referred to as GAS, or group A strep.




Figure 22.5 This scanning electron micrograph of *Streptococcus pyogenes* shows the characteristic cellular phenotype resembling chains of cocci. (credit: modification of work by U.S. Centers for Disease Control and Prevention - Medical Illustrator)

Similar to streptococcal infections of the skin, the mucosal membranes of the pharynx are damaged by the release of a variety of exoenzymes and exotoxins by this extracellular pathogen. Many strains of *S. pyogenes* can degrade connective tissues by using hyaluronidase, collagenase and streptokinase. Streptokinase activates plasmin, which leads to degradation of fibrin and, in turn, dissolution of blood clots, which assists in the spread of the pathogen. Released toxins include streptolysins that can destroy red and white blood cells. The classic signs of streptococcal pharyngitis are a fever higher than 38 °C (100.4 °F); intense pharyngeal pain; erythema associated with pharyngeal inflammation; and swollen, dark-red palatine tonsils, often dotted with patches of pus; and petechiae (microcapillary hemorrhages) on the soft or hard palate (roof of the mouth) ([Figure 22.6](#)). The submandibular lymph nodes beneath the angle of the jaw are also often swollen during strep throat.

Some strains of group A streptococci produce **erythrogenic toxin**. This exotoxin is encoded by a temperate bacteriophage (bacterial virus) and is an example of phage conversion (see [The Viral Life Cycle](#)). The toxin attacks the plasma membranes of capillary endothelial cells and leads to **scarlet fever** (or scarlatina), a disseminated fine red rash on the skin, and strawberry tongue, a red rash on the tongue ([Figure 22.6](#)). Severe cases may even lead to streptococcal toxic shock syndrome (STSS), which results from massive superantigen production that leads to septic shock and death.

S. pyogenes can be easily spread by direct contact or droplet transmission through coughing and sneezing. The disease can be diagnosed quickly using a rapid enzyme immunoassay for the group A antigen. However, due to a significant rate of false-negative results (up to 30%⁴), culture identification is still the gold standard to confirm pharyngitis due to *S. pyogenes*. *S. pyogenes* can be identified as a catalase-negative, beta hemolytic bacterium that is susceptible to 0.04 units of bacitracin. Antibiotic resistance is limited for this bacterium, so most β -lactams remain effective; oral amoxicillin and intramuscular penicillin G are those most commonly prescribed.

4 WL Lean et al. "Rapid Diagnostic Tests for Group A Streptococcal Pharyngitis: A Meta-Analysis." *Pediatrics* 134, no. 4 (2014):771–781.




Figure 22.6 Streptococcal infections of the respiratory tract may cause localized pharyngitis or systemic signs and symptoms. (a) The characteristic appearance of strep throat: bright red arches of inflammation with the presence of dark-red spots (petechiae). (b) Scarlet fever presents as a rash on the skin. (credit a: modification of work by Centers for Disease Control and Prevention; credit b: modification of work by Alicia Williams)

Sequelae of *S. pyogenes* Infections

One reason strep throat infections are aggressively treated with antibiotics is because they can lead to serious **sequelae**, later clinical consequences of a primary infection. It is estimated that 1%–3% of untreated *S. pyogenes* infections can be followed by nonsuppurative (without the production of pus) sequelae that develop 1–3 weeks after the acute infection has resolved. Two such sequelae are **acute rheumatic fever** and **acute glomerulonephritis**.

Acute rheumatic fever can follow pharyngitis caused by specific rheumatogenic strains of *S. pyogenes* (strains 1, 3, 5, 6, and 18). Although the exact mechanism responsible for this sequela remains unclear, molecular mimicry between the M protein of rheumatogenic strains of *S. pyogenes* and heart tissue is thought to initiate the autoimmune attack. The most serious and lethal clinical manifestation of rheumatic fever is damage to and inflammation of the heart (carditis). Acute glomerulonephritis also results from an immune response to streptococcal antigens following pharyngitis and cutaneous infections. Acute glomerulonephritis develops within 6–10 days after pharyngitis, but can take up to 21 days after a cutaneous infection. Similar to acute rheumatic fever, there are strong associations between specific nephritogenic strains of *S. pyogenes* and acute glomerulonephritis, and evidence suggests a role for antigen mimicry and autoimmunity. However, the primary mechanism of acute glomerulonephritis appears to be the formation of immune complexes between *S. pyogenes* antigens and antibodies, and their deposition between endothelial cells of the glomeruli of kidney. Inflammatory response against the immune complexes leads to damage and inflammation of the glomeruli (glomerulonephritis).

✓ CHECK YOUR UNDERSTANDING

- What are the symptoms of strep throat?
- What is erythrogenic toxin and what effect does it have?
- What are the causes of rheumatic fever and acute glomerulonephritis?

Acute Otitis Media

An infection of the middle ear is called **acute otitis media (AOM)**, but often it is simply referred to as an earache. The condition is most common between ages 3 months and 3 years. In the United States, AOM is the second-leading cause of visits to pediatricians by children younger than age 5 years, and it is the leading indication for antibiotic prescription.⁵

5 G. Worrall. "Acute Otitis Media." *Canadian Family Physician* 53 no. 12 (2007):2147–2148.

AOM is characterized by the formation and accumulation of pus in the middle ear. Unable to drain, the pus builds up, resulting in moderate to severe bulging of the tympanic membrane and otalgia (ear pain). Inflammation resulting from the infection leads to swelling of the eustachian tubes, and may also lead to fever, nausea, vomiting, and diarrhea, particularly in infants. Infants and toddlers who cannot yet speak may exhibit nonverbal signs suggesting AOM, such as holding, tugging, or rubbing of the ear, as well as uncharacteristic crying or distress in response to the pain.

AOM can be caused by a variety of bacteria. Among neonates, *S. pneumoniae* is the most common cause of AOM, but *Escherichia coli*, *Enterococcus* spp., and group B *Streptococcus* species can also be involved. In older infants and children younger than 14 years old, the most common bacterial causes are *S. pneumoniae*, *Haemophilus influenzae*, or *Moraxella catarrhalis*. Among *S. pneumoniae* infections, encapsulated strains are frequent causes of AOM. By contrast, the strains of *H. influenzae* and *M. catarrhalis* that are responsible for AOM do not possess a capsule. Rather than direct tissue damage by these pathogens, bacterial components such as lipopolysaccharide (LPS) in gram-negative pathogens induce an inflammatory response that causes swelling, pus, and tissue damage within the middle ear ([Figure 22.7](#)).

Any blockage of the eustachian tubes, with or without infection, can cause fluid to become trapped and accumulate in the middle ear. This is referred to as **otitis media with effusion (OME)**. The accumulated fluid offers an excellent reservoir for microbial growth and, consequently, secondary bacterial infections often ensue. This can lead to recurring and chronic earaches, which are especially common in young children. The higher incidence in children can be attributed to many factors. Children have more upper respiratory infections, in general, and their eustachian tubes are also shorter and drain at a shallower angle. Young children also tend to spend more time lying down than adults, which facilitates drainage from the nasopharynx through the eustachian tube and into the middle ear. Bottle feeding while lying down enhances this risk because the sucking action on the bottle causes negative pressure to build up within the eustachian tube, promoting the movement of fluid and bacteria from the nasopharynx.

Diagnosis is typically made based on clinical signs and symptoms, without laboratory testing to determine the specific causative agent. Antibiotics are frequently prescribed for the treatment of AOM. High-dose amoxicillin is the first-line drug, but with increasing resistance concerns, macrolides and cephalosporins may also be used. The pneumococcal conjugate vaccine (PCV13) contains serotypes that are important causes of AOM, and vaccination has been shown to decrease the incidence of AOM. Vaccination against influenza has also been shown to decrease the risk for AOM, likely because viral infections like influenza predispose patients to secondary infections with *S. pneumoniae*. Although there is a conjugate vaccine available for the invasive serotype B of *H. influenzae*, this vaccine does not impact the incidence of *H. influenzae* AOM. Because unencapsulated strains of *H. influenzae* and *M. catarrhalis* are involved in AOM, vaccines against bacterial cellular factors other than capsules will need to be developed.




Figure 22.7 (a) A healthy tympanic membrane; the middle ear bones can be seen behind the membrane. (b) An ear with chronic inflammation that has resulted in a torn membrane, erosion of the inner ear bones, and mucus buildup. (credit a: modification of work by “DrER.tv”/YouTube; credit b: modification of work by Li Mg, Hotez PJ, Vrabec JT, Donovan DT)

Bacterial Rhinosinusitis

The microbial community of the nasopharynx is extremely diverse and harbors many opportunistic pathogens, so it is perhaps not surprising that infections leading to rhinitis and sinusitis have many possible causes. These conditions often occur as secondary infections after a viral infection, which effectively compromises the immune defenses and allows the opportunistic bacteria to establish themselves. Bacterial sinusitis involves infection and inflammation within the paranasal sinuses. Because bacterial sinusitis rarely occurs without rhinitis, the preferred term is rhinosinusitis. The most common causes of bacterial rhinosinusitis are similar to those for AOM, including *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis*.

✓ CHECK YOUR UNDERSTANDING

- What are the usual causative agents of acute otitis media?
- What factors facilitate acute otitis media with effusion in young children?
- What factor often triggers bacterial rhinosinusitis?

Diphtheria

The causative agent of **diphtheria**, *Corynebacterium diphtheriae*, is a club-shaped, gram-positive rod that belongs to the phylum Actinobacteria. Diphtheroids are common members of the normal nasopharyngeal microbiota. However, some strains of *C. diphtheriae* become pathogenic because of the presence of a temperate bacteriophage-encoded protein—the diphtheria toxin. Diphtheria is typically a respiratory infection of the oropharynx but can also cause impetigo-like lesions on the skin. Although the disease can affect people of all ages, it tends to be most severe in those younger than 5 years or older than 40 years. Like strep throat, diphtheria is commonly transmitted in the droplets and aerosols produced by coughing. After colonizing the throat, the bacterium remains in the oral cavity and begins producing the diphtheria toxin. This protein is an A-B toxin that blocks host-cell protein synthesis by inactivating elongation factor (EF)-2 (see [Virulence Factors of Bacterial and Viral Pathogens](#)). The toxin’s action leads to the death of the host cells and an inflammatory response. An accumulation of grayish exudate consisting of dead host cells, pus, red blood cells, fibrin, and infectious bacteria results in the formation of a **pseudomembrane**. The pseudomembrane can cover mucous membranes of the nasal cavity, tonsils, pharynx, and larynx ([Figure 22.8](#)). This is a classic sign of diphtheria.

As the disease progresses, the pseudomembrane can enlarge to obstruct the fauces of the pharynx or trachea and can lead to suffocation and death. Sometimes, **intubation**, the placement of a breathing tube in the trachea, is required in advanced infections. If the diphtheria toxin spreads throughout the body, it can damage other tissues as well. This can include myocarditis (heart damage) and nerve damage that may impair breathing.




Figure 22.8 The pseudomembrane in a patient with diphtheria presents as a leathery gray patch consisting of dead cells, pus, fibrin, red blood cells, and infectious microbes. (credit: modification of work by Putnong N, Agustin G, Pasubillo M, Miyagi K, Dimaano EM)

The presumptive diagnosis of diphtheria is primarily based on the clinical symptoms (i.e., the pseudomembrane) and vaccination history, and is typically confirmed by identifying bacterial cultures obtained from throat swabs. The diphtheria toxin itself can be directly detected *in vitro* using polymerase chain reaction (PCR)-based, direct detection systems for the diphtheria *tox* gene, and immunological techniques like radial immunodiffusion or Elek's immunodiffusion test.

Broad-spectrum antibiotics like penicillin and erythromycin tend to effectively control *C. diphtheriae* infections. Regrettably, they have no effect against preformed toxins. If toxin production has already occurred in the patient, antitoxins (preformed antibodies against the toxin) are administered. Although this is effective in neutralizing the toxin, the antitoxins may lead to serum sickness because they are produced in horses (see [Hypersensitivities](#)).

Widespread vaccination efforts have reduced the occurrence of diphtheria worldwide. There are currently four combination toxoid vaccines available that provide protection against diphtheria and other diseases: DTaP, Tdap, DT, and Td. In all cases, the letters “d,” “t,” and “p” stand for diphtheria, tetanus, and pertussis, respectively; the “a” stands for acellular. If capitalized, the letters indicate a full-strength dose; lowercase letters indicate reduced dosages. According to current recommendations, children should receive five doses of the DTaP vaccine in their youth and a Td booster every 10 years. Children with adverse reactions to the pertussis vaccine may be given the DT vaccine in place of the DTaP.

✓ CHECK YOUR UNDERSTANDING

- What effect does diphtheria toxin have?
- What is the pseudomembrane composed of?

Bacterial Pneumonia

Pneumonia is a general term for infections of the lungs that lead to inflammation and accumulation of fluids and white blood cells in the alveoli. Pneumonia can be caused by bacteria, viruses, fungi, and other organisms, although the vast majority of pneumonias are bacterial in origin. Bacterial pneumonia is a prevalent, potentially serious infection; it caused more 50,000 deaths in the United States in 2014.⁶ As the alveoli fill with fluids and white blood cells (consolidation), air exchange becomes impaired and patients experience respiratory distress (Figure 22.9). In addition, pneumonia can lead to pleurisy, an infection of the pleural membrane surrounding the lungs, which can make breathing very painful. Although many different bacteria can cause pneumonia under the right circumstances, three bacterial species cause most clinical cases: *Streptococcus pneumoniae*, *H. influenzae*, and *Mycoplasma pneumoniae*. In addition to these, we will also examine some of the less common causes of pneumonia.




Figure 22.9 A chest radiograph of a patient with pneumonia shows the consolidations (lesions) present as opaque patches. (credit: modification of work by Centers for Disease Control and Prevention)

Pneumococcal Pneumonia

The most common cause of community-acquired bacterial pneumonia is *Streptococcus pneumoniae*. This gram-positive, alpha hemolytic streptococcus is commonly found as part of the normal microbiota of the human respiratory tract. The cells tend to be somewhat lancet-shaped and typically appear as pairs (Figure 22.10). The pneumococci initially colonize the bronchioles of the lungs. Eventually, the infection spreads to the alveoli, where the microbe's polysaccharide capsule interferes with phagocytic clearance. Other virulence factors include autolysins like Lyt A, which degrade the microbial cell wall, resulting in cell lysis and the release of cytoplasmic virulence factors. One of these factors, pneumolysin O, is important in disease progression; this pore-forming protein damages host cells, promotes bacterial adherence, and enhances pro-inflammatory cytokine production. The resulting inflammatory response causes the alveoli to fill with exudate rich in neutrophils and red blood cells. As a consequence, infected individuals develop a productive cough with bloody sputum.

6 KD Kochanek et al. "Deaths: Final Data for 2014." *National Vital Statistics Reports* 65 no 4 (2016).




Figure 22.10 (a) This micrograph of *Streptococcus pneumoniae* grown from a blood culture shows the characteristic lancet-shaped diplococcal morphology. (b) A colorized scanning electron micrograph of *S. pneumoniae*. (credit a: modification of work by Centers for Disease Control and Prevention; credit b: modification of work by Janice Carr, Centers for Disease Control and Prevention)

Pneumococci can be presumptively identified by their distinctive gram-positive, lancet-shaped cell morphology and diplococcal arrangement. In blood agar cultures, the organism demonstrates alpha hemolytic colonies that are autolytic after 24 to 48 hours. In addition, *S. pneumoniae* is extremely sensitive to optochin and colonies are rapidly destroyed by the addition of 10% solution of sodium deoxycholate. All clinical pneumococcal isolates are serotyped using the quellung reaction with typing antisera produced by the CDC. Positive quellung reactions are considered definitive identification of pneumococci.

Antibiotics remain the mainstay treatment for pneumococci. β -Lactams like penicillin are the first-line drugs, but resistance to β -lactams is a growing problem. When β -lactam resistance is a concern, macrolides and fluoroquinolones may be prescribed. However, *S. pneumoniae* resistance to macrolides and fluoroquinolones is increasing as well, limiting the therapeutic options for some infections. There are currently two pneumococcal vaccines available: pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). These are generally given to the most vulnerable populations of individuals: children younger than 2 years and adults older than 65 years.

Haemophilus Pneumonia

Encapsulated strains of *Haemophilus influenzae* are known for causing meningitis, but nonencapsulated strains are important causes of pneumonia. This small, gram-negative coccobacillus is found in the pharynx of the majority of healthy children; however, *Haemophilus pneumonia* is primarily seen in the elderly. Like other pathogens that cause pneumonia, *H. influenzae* is spread by droplets and aerosols produced by coughing. A fastidious organism, *H. influenzae* will only grow on media with available factor X (hemin) and factor V (NAD), like chocolate agar (Figure 22.11). Serotyping must be performed to confirm identity of *H. influenzae* isolates.

Infections of the alveoli by *H. influenzae* result in inflammation and accumulation of fluids. Increasing resistance to β -lactams, macrolides, and tetracyclines presents challenges for the treatment of *Haemophilus pneumonia*. Resistance to the fluoroquinolones is rare among isolates of *H. influenzae* but has been observed. As discussed for AOM, a vaccine directed against nonencapsulated *H. influenzae*, if developed, would provide protection against pneumonia caused by this pathogen.



Figure 22.11 Culture of *Haemophilus influenzae* on a chocolate agar plate. (credit: modification of work by Centers for Disease Control and Prevention)

Case in Point

Why Me?

Tracy is a 6-year old who developed a serious cough that would not seem to go away. After 2 weeks, her parents became concerned and took her to the pediatrician, who suspected a case of bacterial pneumonia. Tests confirmed that the cause was *Haemophilus influenzae*. Fortunately, Tracy responded well to antibiotic treatment and eventually made a full recovery.

Because there had been several other cases of bacterial pneumonia at Tracy's elementary school, local health officials urged parents to have their children screened. Of the children who were screened, it was discovered that greater than 50% carried *H. influenzae* in their nasal cavities, yet all but two of them were asymptomatic.

Why is it that some individuals become seriously ill from bacterial infections that seem to have little or no effect on others? The pathogenicity of an organism—its ability to cause host damage—is not solely a property of the microorganism. Rather, it is the product of a complex relationship between the microbe's virulence factors and the immune defenses of the individual. Preexisting conditions and environmental factors such as exposure to secondhand smoke can make some individuals more susceptible to infection by producing conditions favorable to microbial growth or compromising the immune system. In addition, individuals may have genetically determined immune factors that protect them—or not—from particular strains of pathogens. The interactions between these host factors and the pathogenicity factors produced by the microorganism ultimately determine the outcome of the infection. A clearer understanding of these interactions may allow for better identification of at-risk individuals and prophylactic interventions in the future.

Mycoplasma Pneumonia (Walking Pneumonia)

Primary atypical pneumonia is caused by *Mycoplasma pneumoniae*. This bacterium is not part of the respiratory tract's normal microbiota and can cause epidemic disease outbreaks. Also known as walking pneumonia, ***mycoplasma pneumonia*** infections are common in crowded environments like college campuses and military bases. It is spread by aerosols formed when coughing or sneezing. The disease is often mild, with a low fever and persistent cough. These bacteria, which do not have cell walls, use a specialized attachment organelle to bind to ciliated cells. In the process, epithelial cells are damaged and the proper function of the cilia is hindered ([Figure 22.12](#)).

Mycoplasma grow very slowly when cultured. Therefore, penicillin and thallium acetate are added to agar to prevent the overgrowth by faster-growing potential contaminants. Since *M. pneumoniae* does not have a cell wall, it is resistant to these substances. Without a cell wall, the microbial cells appear pleomorphic. *M. pneumoniae* infections tend to be self-limiting but may also respond well to macrolide antibiotic therapy. β -lactams, which target cell wall synthesis, are not indicated for treatment of infections with this pathogen.




Figure 22.12 The micrograph shows *Mycoplasma pneumoniae* using their specialized receptors to attach to epithelial cells in the trachea of an infected hamster. (credit: modification of work by American Society for Microbiology)

Chlamydial Pneumonias and Psittacosis

Chlamydial pneumonia can be caused by three different species of bacteria: *Chlamydophila pneumoniae* (formerly known as *Chlamydia pneumoniae*), *Chlamydophila psittaci* (formerly known as *Chlamydia psittaci*), and *Chlamydia trachomatis*. All three are obligate intracellular pathogens and cause mild to severe pneumonia and bronchitis. Of the three, *Chlamydophila pneumoniae* is the most common and is transmitted via respiratory droplets or aerosols. *C. psittaci* causes **psittacosis**, a zoonotic disease that primarily affects domesticated birds such as parakeets, turkeys, and ducks, but can be transmitted from birds to humans. Psittacosis is a relatively rare infection and is typically found in people who work with birds. *Chlamydia trachomatis*, the causative agent of the sexually transmitted disease chlamydia, can cause pneumonia in infants when the infection is passed from mother to baby during birth.

Diagnosis of chlamydia by culturing tends to be difficult and slow. Because they are intracellular pathogens, they require multiple passages through tissue culture. Recently, a variety of PCR- and serologically based tests have been developed to enable easier identification of these pathogens. Tetracycline and macrolide antibiotics are typically prescribed for treatment.

Health Care-Associated Pneumonia

A variety of opportunistic bacteria that do not typically cause respiratory disease in healthy individuals are common causes of health care-associated pneumonia. These include *Klebsiella pneumoniae*, *Staphylococcus aureus*, and proteobacteria such as species of *Escherichia*, *Proteus*, and *Serratia*. Patients at risk include the elderly, those who have other preexisting lung conditions, and those who are immunocompromised. In addition, patients receiving supportive therapies such as intubation, antibiotics, and immunomodulatory drugs may also be at risk because these interventions disrupt the mucociliary escalator and other pulmonary defenses. Invasive medical devices such as catheters, medical implants, and ventilators can also introduce opportunistic pneumonia-causing pathogens into the body.⁷

Pneumonia caused by *K. pneumoniae* is characterized by lung necrosis and “currant jelly sputum,” so named

7 SM Koenig et al. “Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention.” *Clinical Microbiology Reviews* 19 no.

because it consists of clumps of blood, mucus, and debris from the thick polysaccharide capsule produced by the bacterium. *K. pneumoniae* is often multidrug resistant. Aminoglycoside and cephalosporin are often prescribed but are not always effective. *Klebsiella pneumoniae* is frequently fatal even when treated.

Pseudomonas Pneumonia

Pseudomonas aeruginosa is another opportunistic pathogen that can cause serious cases of bacterial pneumonia in patients with cystic fibrosis (CF) and hospitalized patients assisted with artificial ventilators. This bacterium is extremely antibiotic resistant and can produce a variety of exotoxins. Ventilator-associated pneumonia with *P. aeruginosa* is caused by contaminated equipment that causes the pathogen to be aspirated into the lungs. In patients with CF, a genetic defect in the cystic fibrosis transmembrane receptor (CFTR) leads to the accumulation of excess dried mucus in the lungs. This decreases the effectiveness of the defensins and inhibits the mucociliary escalator. *P. aeruginosa* is known to infect more than half of all patients with CF. It adapts to the conditions in the patient's lungs and begins to produce alginate, a viscous exopolysaccharide that inhibits the mucociliary escalator. Lung damage from the chronic inflammatory response that ensues is the leading cause of mortality in patients with CF.⁸

CHECK YOUR UNDERSTANDING

- What three pathogens are responsible for the most prevalent types of bacterial pneumonia?
- Which cause of pneumonia is most likely to affect young people?
- In what contexts does *Pseudomonas aeruginosa* cause pneumonia?

Clinical Focus

Part 2

John's chest radiograph revealed an extensive consolidation in the right lung, and his sputum cultures revealed the presence of a gram-negative rod. His physician prescribed a course of the antibiotic clarithromycin. He also ordered the rapid influenza diagnostic tests (RIDTs) for type A and B influenza to rule out a possible underlying viral infection. Despite antibiotic therapy, John's condition continued to deteriorate, so he was admitted to the hospital.

- What are some possible causes of pneumonia that would not have responded to the prescribed antibiotic?

Jump to the [next](#) Clinical Focus box. Go back to the [previous](#) Clinical Focus box.

Tuberculosis

Tuberculosis (TB) is one of the deadliest infectious diseases in human history. Although **tuberculosis** infection rates in the United States are extremely low, the CDC estimates that about one-third of the world's population is infected with *Mycobacterium tuberculosis*, the causal organism of TB, with 9.6 million new TB cases and 1.5 million deaths worldwide in 2014.⁹

M. tuberculosis is an acid-fast, high G + C, gram-positive, nonspore-forming rod. Its cell wall is rich in waxy mycolic acids, which make the cells impervious to polar molecules. It also causes these organisms to grow slowly. *M. tuberculosis* causes a chronic granulomatous disease that can infect any area of the body, although it is typically associated with the lungs. *M. tuberculosis* is spread by inhalation of respiratory droplets or aerosols from an infected person. The infectious dose of *M. tuberculosis* is only 10 cells.¹⁰

4 (2006):637–657.

8 R. Sordé et al. "Management of Refractory *Pseudomonas aeruginosa* Infection in Cystic Fibrosis." *Infection and Drug Resistance* 4 (2011):31–41.

9 Centers for Disease Control and Prevention. "Tuberculosis (TB). Data and Statistics." <http://www.cdc.gov/tb/statistics/default.htm>

10 D. Saini et al. "Ultra-Low Dose of *Mycobacterium tuberculosis* Aerosol Creates Partial Infection in Mice." *Tuberculosis* 92 no. 2

After inhalation, the bacteria enter the alveoli ([Figure 22.13](#)). The cells are phagocytized by macrophages but can survive and multiply within these phagocytes because of the protection by the waxy mycolic acid in their cell walls. If not eliminated by macrophages, the infection can progress, causing an inflammatory response and an accumulation of neutrophils and macrophages in the area. Several weeks or months may pass before an immunological response is mounted by T cells and B cells. Eventually, the lesions in the alveoli become walled off, forming small round lesions called **tubercles**. Bacteria continue to be released into the center of the tubercles and the chronic immune response results in tissue damage and induction of apoptosis (programmed host-cell death) in a process called liquefaction. This creates a caseous center, or air pocket, where the aerobic *M. tuberculosis* can grow and multiply. Tubercles may eventually rupture and bacterial cells can invade pulmonary capillaries; from there, bacteria can spread through the bloodstream to other organs, a condition known as **miliary tuberculosis**. The rupture of tubercles also facilitates transmission of the bacteria to other individuals via droplet aerosols that exit the body in coughs. Because these droplets can be very small and stay aloft for a long time, special precautions are necessary when caring for patients with TB, such as the use of face masks and negative-pressure ventilation and filtering systems.

Eventually, most lesions heal to form calcified **Ghon complexes**. These structures are visible on chest radiographs and are a useful diagnostic feature. But even after the disease has apparently ended, viable bacteria remain sequestered in these locations. Release of these organisms at a later time can produce **reactivation tuberculosis** (or secondary TB). This is mainly observed in people with alcoholism, the elderly, or in otherwise immunocompromised individuals ([Figure 22.13](#)).




Figure 22.13 In the infectious cycle of tuberculosis, the immune response of most infected individuals (approximately 90%) results in the formation of tubercles in which the infection is walled off.¹¹ The remainder will suffer progressive primary tuberculosis. The sequestered bacteria may be reactivated to form secondary tuberculosis in immunocompromised patients at a later time. (credit: modification of work by Centers for Disease Control and Prevention)

Because TB is a chronic disease, chemotherapeutic treatments often continue for months or years. Multidrug resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of *M. tuberculosis* are a growing clinical concern. These strains can arise due to misuse or mismanagement of antibiotic therapies. Therefore, it is imperative that proper multidrug protocols are used to treat these infections. Common antibiotics included in these mixtures are isoniazid, rifampin, ethambutol, and pyrazinamide.

A TB vaccine is available that is based on the so-called bacillus Calmette-Guérin (BCG) strain of *M. bovis* commonly found in cattle. In the United States, the BCG vaccine is only given to health-care workers and members of the military who are at risk of exposure to active cases of TB. It is used more broadly worldwide. Many individuals born in other countries have been vaccinated with BCG strain. BCG is used in many countries with a high prevalence of TB, to prevent childhood tuberculous meningitis and miliary disease.

11 G. Kaplan et al. "Mycobacterium tuberculosis Growth at the Cavity Surface: A Microenvironment with Failed Immunity." *Infection and Immunity* 71 no.12 (2003):7099–7108.

The Mantoux tuberculin skin test (Figure 22.14) is regularly used in the United States to screen for potential TB exposure (see [Hypersensitivities](#)). However, prior vaccinations with the BCG vaccine can cause false-positive results. Chest radiographs to detect Ghon complex formation are required, therefore, to confirm exposure.



Figure 22.14 (a) The Mantoux skin test for tuberculosis involves injecting the subject with tuberculin protein derivative. The injection should initially produce a raised wheal. (b) The test should be read in 48–72 hours. A positive result is indicated by redness, swelling, or hardness; the size of the responding region is measured to determine the final result. (credit a, b: modification of work by Centers for Disease Control and Prevention)

LINK TO LEARNING

This short [animation \(https://openstax.org/l/22mycotublegpnean\)](https://openstax.org/l/22mycotublegpnean) describes the mechanisms of infection associated with *Mycobacterium tuberculosis*.

CHECK YOUR UNDERSTANDING

- What characteristic of *Mycobacterium tuberculosis* allows it to evade the immune response?
- What happens to cause miliary tuberculosis?
- Explain the limitations of the Mantoux tuberculin skin test.

Pertussis (Whooping Cough)

The causative agent of **pertussis**, commonly called **whooping cough**, is *Bordetella pertussis*, a gram-negative coccobacillus. The disease is characterized by mucus accumulation in the lungs that leads to a long period of severe coughing. Sometimes, following a bout of coughing, a sound resembling a “whoop” is produced as air is inhaled through the inflamed and restricted airway—hence the name whooping cough. Although adults can be infected, the symptoms of this disease are most pronounced in infants and children. Pertussis is highly communicable through droplet transmission, so the uncontrollable coughing produced is an efficient means of transmitting the disease in a susceptible population.

Following inhalation, *B. pertussis* specifically attaches to epithelial cells using an adhesin, filamentous hemagglutinin. The bacteria then grow at the site of infection and cause disease symptoms through the production of exotoxins. One of the main virulence factors of this organism is an A-B exotoxin called the **pertussis toxin (PT)**. When PT enters the host cells, it increases the cyclic adenosine monophosphate (cAMP) levels and disrupts cellular signaling. PT is known to enhance inflammatory responses involving histamine and serotonin. In addition to PT, *B. pertussis* produces a tracheal cytotoxin that damages ciliated epithelial cells and results in accumulation of mucus in the lungs. The mucus can support the colonization and growth of other microbes and, as a consequence, secondary infections are common. Together, the effects of these factors produce the cough that characterizes this infection.

A pertussis infection can be divided into three distinct stages. The initial infection, termed the **catarrhal stage**, is relatively mild and unremarkable. The signs and symptoms may include nasal congestion, a runny nose, sneezing, and a low-grade fever. This, however, is the stage in which *B. pertussis* is most infectious. In the

paroxysmal stage, mucus accumulation leads to uncontrollable coughing spasms that can last for several minutes and frequently induce vomiting. The paroxysmal stage can last for several weeks. A long **convalescence stage** follows the paroxysmal stage, during which time patients experience a chronic cough that can last for up to several months. In fact, the disease is sometimes called the 100-day cough.

In infants, coughing can be forceful enough to cause fractures to the ribs, and prolonged infections can lead to death. The CDC reported 20 pertussis-related deaths in 2012,¹² but that number had declined to five by 2015.¹³

During the first 2 weeks of infection, laboratory diagnosis is best performed by culturing the organism directly from a nasopharyngeal (NP) specimen collected from the posterior nasopharynx. The NP specimen is streaked onto Bordet-Gengou medium. The specimens must be transported to the laboratory as quickly as possible, even if transport media are used. Transport times of longer than 24 hours reduce the viability of *B. pertussis* significantly.

Within the first month of infection, *B. pertussis* can be diagnosed using PCR techniques. During the later stages of infection, pertussis-specific antibodies can be immunologically detected using an enzyme-linked immunosorbent assay (ELISA).

Pertussis is generally a self-limiting disease. Antibiotic therapy with erythromycin or tetracycline is only effective at the very earliest stages of disease. Antibiotics given later in the infection, and prophylactically to uninfected individuals, reduce the rate of transmission. Active vaccination is a better approach to control this disease. The DPT vaccine was once in common use in the United States. In that vaccine, the P component consisted of killed whole-cell *B. pertussis* preparations. Because of some adverse effects, that preparation has now been superseded by the DTaP and Tdap vaccines. In both of these new vaccines, the “aP” component is a pertussis toxoid.

Widespread vaccination has greatly reduced the number of reported cases and prevented large epidemics of pertussis. Recently, however, pertussis has begun to reemerge as a childhood disease in some states because of declining vaccination rates and an increasing population of susceptible children.

LINK TO LEARNING

This [web page \(https://openstax.org/l/22pertussaudio\)](https://openstax.org/l/22pertussaudio) contains an audio clip of the distinctive “whooping” sound associated with pertussis in infants.

This interactive [map \(https://openstax.org/l/22intmapprevacc\)](https://openstax.org/l/22intmapprevacc) shows outbreaks of vaccine preventable diseases, including pertussis, around the world.

CHECK YOUR UNDERSTANDING

- What accounts for the mucus production in a pertussis infection?
- What are the signs and symptoms associated with the three stages of pertussis?
- Why is pertussis becoming more common in the United States?

Legionnaires Disease

An atypical pneumonia called **Legionnaires disease** (also known as legionellosis) is caused by an aerobic gram-negative bacillus, *Legionella pneumophila*. This bacterium infects free-living amoebae that inhabit moist environments, and infections typically occur from human-made reservoirs such as air-conditioning cooling towers, humidifiers, misting systems, and fountains. Aerosols from these reservoirs can lead to infections of susceptible individuals, especially those suffering from chronic heart or lung disease or other

12 Centers for Disease Control and Prevention. “2012 Final Pertussis Surveillance Report.” 2015. <http://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2012.pdf>. Accessed July 6, 2016.

13 Centers for Disease Control and Prevention. “2015 Provisional Pertussis Surveillance Report.” 2016. <http://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2015-provisional.pdf>. Accessed July 6, 2016.

conditions that weaken the immune system.

When *L. pneumophila* bacteria enter the alveoli, they are phagocytized by resident macrophages. However, *L. pneumophila* uses a secretion system to insert proteins in the endosomal membrane of the macrophage; these proteins prevent lysosomal fusion, allowing *L. pneumophila* to continue to proliferate within the phagosome. The resulting respiratory disease can range from mild to severe pneumonia, depending on the status of the host's immune defenses. Although this disease primarily affects the lungs, it can also cause fever, nausea, vomiting, confusion, and other neurological effects.

Diagnosis of Legionnaires disease is somewhat complicated. *L. pneumophila* is a fastidious bacterium and is difficult to culture. In addition, since the bacterial cells are not efficiently stained with the Gram stain, other staining techniques, such as the Warthin-Starry silver-precipitate procedure, must be used to visualize this pathogen. A rapid diagnostic test has been developed that detects the presence of *Legionella* antigen in a patient's urine; results take less than 1 hour, and the test has high selectivity and specificity (greater than 90%). Unfortunately, the test only works for one serotype of *L. pneumophila* (type 1, the serotype responsible for most infections). Consequently, isolation and identification of *L. pneumophila* from sputum remains the defining test for diagnosis.

Once diagnosed, Legionnaire disease can be effectively treated with fluoroquinolone and macrolide antibiotics. However, the disease is sometimes fatal; about 10% of patients die of complications.¹⁴ There is currently no vaccine available.

CHECK YOUR UNDERSTANDING

- Why is Legionnaires disease associated with air-conditioning systems?
- How does *Legionella pneumophila* circumvent the immune system?

Q Fever

The zoonotic disease **Q fever** is caused by a rickettsia, *Coxiella burnetii*. The primary reservoirs for this bacterium are domesticated livestock such as cattle, sheep, and goats. The bacterium may be transmitted by ticks or through exposure to the urine, feces, milk, or amniotic fluid of an infected animal. In humans, the primary route of infection is through inhalation of contaminated farmyard aerosols. It is, therefore, largely an occupational disease of farmers. Humans are acutely sensitive to *C. burnetii*—the infective dose is estimated to be just a few cells.¹⁵ In addition, the organism is hardy and can survive in a dry environment for an extended time. Symptoms associated with acute Q fever include high fever, headache, coughing, pneumonia, and general malaise. In a small number of patients (less than 5%¹⁶), the condition may become chronic, often leading to endocarditis, which may be fatal.

Diagnosing rickettsial infection by cultivation in the laboratory is both difficult and hazardous because of the easy aerosolization of the bacteria, so PCR and ELISA are commonly used. Doxycycline is the first-line drug to treat acute Q fever. In chronic Q fever, doxycycline is often paired with hydroxychloroquine.

Disease Profile

Bacterial Diseases of the Respiratory Tract

Numerous pathogens can cause infections of the respiratory tract. Many of these infections produce similar signs and symptoms, but appropriate treatment depends on accurate diagnosis through laboratory testing. The tables in [Figure 22.15](#) and [Figure 22.16](#) summarize the most important bacterial respiratory

14 Centers for Disease Control and Prevention. "Legionella (Legionnaires' Disease and Pontiac Fever: Diagnosis, Treatment, and Complications)." <http://www.cdc.gov/legionella/about/diagnosis.html>. Accessed Sept 14, 2016.

15 WD Tigertt et al. "Airborne Q Fever." *Bacteriological Reviews* 25 no. 3 (1961):285–293.

16 Centers for Disease Control and Prevention. "Q fever. Symptoms, Diagnosis, and Treatment." 2013. <http://www.cdc.gov/qfever/symptoms/index.html>. Accessed July 6, 2016.

infections, with the latter focusing specifically on forms of bacterial pneumonia.

Bacterial Infections of the Respiratory Tract						
Disease	Pathogen	Signs and Symptoms	Transmission	Diagnostic Tests	Antimicrobial Drugs	Vaccine
Acute otitis media (AOM)	<i>Haemophilus influenzae</i> , <i>Streptococcus pneumoniae</i> , <i>Moraxella catarrhalis</i> , others	Earache, possible effusion; may cause fever, nausea, vomiting, diarrhea	Often a secondary infection; bacteria from respiratory tract become trapped in eustachian tube, cause infection	None	Cephalosporins, fluoroquinolones	None
Diphtheria	<i>Corynebacterium diphtheriae</i>	Pseudomembrane on throat, possibly leading to suffocation and death	Inhalation of respiratory droplets or aerosols from infected person	Identification of bacteria in throat swabs; PCR to detect diphtheria toxin in vitro	Erythromycin, penicillin, antitoxin produced in horses	DtaP, Tdap, DT, Td, DTP
Legionnaires disease	<i>Legionella pneumophila</i>	Cough, fever, muscle aches, headaches, nausea, vomiting, confusion; sometimes fatal	Inhalation of aerosols from contaminated water reservoirs	Isolation, using Warthin-Starry procedure, of bacteria in sputum	Fluoroquinolones, macrolides	None
Pertussis (whooping cough)	<i>Bordetella pertussis</i>	Severe coughing with "whoop" sound; chronic cough lasting several months; can be fatal in infants	Inhalation of respiratory droplets from infected person	Direct culture of throat swab, PCR, ELISA	Macrolides	DTaP, Tdap
Q fever	<i>Coxiella burnetii</i>	High fever, coughing, pneumonia, malaise; in chronic cases, potentially fatal endocarditis	Inhalation of aerosols of urine, feces, milk, or amniotic fluid of infected cattle, sheep, goats	PCR, ELISA	Doxycycline, hydroxychloroquine	None
Streptococcal pharyngitis, scarlet fever	<i>Streptococcus pyogenes</i>	Fever, sore throat, inflammation of pharynx and tonsils, petechiae, swollen lymph nodes; skin rash (scarlet fever), strawberry tongue	Direct contact, inhalation of respiratory droplets or aerosols from infected person	Direct culture of throat swab, rapid enzyme immunoassay	β -lactams	None
Tuberculosis	<i>Mycobacterium tuberculosis</i>	Formation of tubercles in lungs; rupture of tubercles, leading to chronic, bloody cough; healed tubercles (Ghon complexes) visible in radiographs; can be fatal	Inhalation of respiratory droplets or aerosols from infected person	Mantoux tuberculin skin test with chest radiograph to identify Ghon complexes	Isoniazid, rifampin, ethambutol, pyrazinamide	BCG

Figure 22.15

Bacterial Causes of Pneumonia						
Disease	Pathogen	Signs and Symptoms	Transmission	Diagnostic Tests	Antimicrobial Drugs	Vaccine
Chlamydial pneumonia	<i>Chlamydomphila pneumoniae</i> , <i>C. psittaci</i> , <i>Chlamydia trachomatis</i>	Bronchitis; mild to severe respiratory distress	Inhalation of respiratory droplets or aerosols from infected person (<i>C. pneumoniae</i>); exposure to infected bird (<i>C. psittaci</i>); exposure in the birth canal (<i>Chlamydia trachomatis</i>)	Tissue culture, PCR	Tetracycline, macrolides	None
Haemophilus pneumonia	<i>Haemophilus influenzae</i>	Cough, fever or low body temperature, chills, chest pain, headache, fatigue	Inhalation of respiratory droplets or aerosols from infected person or asymptomatic carrier	Culture on chocolate agar, serotyping of blood or cerebrospinal fluid samples	Cephalosporins, fluoroquinolones	Hib
Klebsiella pneumonia	<i>Klebsiella pneumoniae</i> , others	Lung necrosis, "currant jelly" sputum; often fatal	Health care associated; bacteria introduced via contaminated ventilators, intubation, or other medical equipment	Culture, PCR	Multidrug resistant; antibiotic susceptibility testing necessary	None
Mycoplasma pneumonia (walking pneumonia)	<i>Mycoplasma pneumoniae</i>	Low fever, persistent cough	Inhalation of respiratory droplets or aerosols from infected person	Culture with penicillin, thallium acetate	Macrolides	None
Pneumococcal pneumonia	<i>Streptococcus pneumoniae</i>	Productive cough, bloody sputum, fever, chills, chest pain, respiratory distress	Direct contact with respiratory secretions	Gram stain, blood agar culture with optichin and sodium deoxycholate, quellung reaction	β -lactams, macrolides, fluoroquinolones	Pneumococcal conjugate vaccine (PCV13), pneumococcal polysaccharide vaccine (PPSV23)
Pseudomonas pneumonia	<i>Pseudomonas aeruginosa</i>	Viscous fluid and chronic inflammation of lungs; often fatal	Health care associated; bacteria introduced via contaminated ventilators; also frequently affects patients with cystic fibrosis	Culture from sputum or other body fluid	Multidrug resistant; antibiotic susceptibility testing necessary	None

Figure 22.16

22.3 Viral Infections of the Respiratory Tract

Learning Objectives

By the end of this section, you will be able to:

- Identify the most common viruses that can cause infections of the upper and lower respiratory tract
- Compare the major characteristics of specific viral diseases of the respiratory tract

Viruses are the most frequent cause of respiratory tract infections. Unlike the bacterial pathogens, we have few effective therapies to combat viral respiratory infections. Fortunately, many of these diseases are mild and self-limiting. A few respiratory infections manifest their primary symptoms at other locations in the body.

The Common Cold

The **common cold** is a generic term for a variety of mild viral infections of the nasal cavity. More than 200 different viruses are known to cause the common cold. The most common groups of cold viruses include rhinoviruses, coronaviruses, and adenoviruses. These infections are widely disseminated in the human population and are transmitted through direct contact and droplet transmission. Coughing and sneezing efficiently produce infectious aerosols, and rhinoviruses are known to persist on environmental surfaces for up to a week.¹⁷

Viral contact with the nasal mucosa or eyes can lead to infection. Rhinoviruses tend to replicate best between 33 °C (91.4 °F) and 35 °C (95 °F), somewhat below normal body temperature (37 °C [98.6 °F]). As a consequence, they tend to infect the cooler tissues of the nasal cavities. Colds are marked by an irritation of the mucosa that leads to an inflammatory response. This produces common signs and symptoms such as nasal excess nasal secretions (runny nose), congestion, sore throat, coughing, and sneezing. The absence of high fever is typically used to differentiate common colds from other viral infections, like influenza. Some colds may progress to cause otitis media, pharyngitis, or laryngitis, and patients may also experience headaches and body aches. The disease, however, is self-limiting and typically resolves within 1–2 weeks.

There are no effective antiviral treatments for the common cold and antibacterial drugs should not be prescribed unless secondary bacterial infections have been established. Many of the viruses that cause colds are related, so immunity develops throughout life. Given the number of viruses that cause colds, however, individuals are never likely to develop immunity to all causes of the common cold.

CHECK YOUR UNDERSTANDING

- How are colds transmitted?
- What is responsible for the symptoms of a cold?

Clinical Focus

Part 3

Since antibiotic treatment had proven ineffective, John's doctor suspects that a viral or fungal pathogen may be the culprit behind John's case of pneumonia. Another possibility is that John could have an antibiotic-resistant bacterial infection that will require a different antibiotic or combination of antibiotics to clear.

The RIDT tests both came back negative for type A and type B influenza. However, the diagnostic laboratory identified the sputum isolate as *Legionella pneumophila*. The doctor ordered tests of John's urine and, on the second day after his admission, results of an enzyme immunoassay (EIA) were positive for the *Legionella* antigen. John's doctor added levofloxacin to his antibiotic therapy and continued to monitor him. The doctor also began to ask John where he had been over the past 10 to 14 days.

17 AG L'Huillier et al. "Survival of Rhinoviruses on Human Fingers." *Clinical Microbiology and Infection* 21, no. 4 (2015):381–385.

- Do negative RIDT results absolutely rule out influenza virus as the etiologic agent? Why or why not?
- What is John's prognosis?

Jump to the [next](#) Clinical Focus box. Go back to the [previous](#) Clinical Focus box.

Influenza

Commonly known as the flu, **influenza** is a common viral disease caused by an orthomyxovirus that primarily affects the upper respiratory tract but can also extend into the lower respiratory tract. Influenza is pervasive worldwide and causes 3,000–50,000 deaths each year in the United States. The annual mortality rate can vary greatly depending on the virulence of the strain(s) responsible for seasonal epidemics.¹⁸

Influenza infections are most typically characterized by fever, chills, and body aches. This is followed by symptoms similar to the common cold that may last a week or more. [Table 22.2](#) compares the signs and symptoms of influenza and the common cold.

Comparing the Common Cold and Influenza

Sign/Symptom	Common Cold	Influenza
Fever	Low (37.2 °C [99 °F])	High (39 °C [102.2 °F])
Headache	Common	Common
Aches and pains	Mild	Severe
Fatigue	Slight	Severe
Nasal congestion	Common	Rare
Sneezing	Common	Rare

Table 22.2

In general, influenza is self-limiting. However, serious cases can lead to pneumonia and other complications that can be fatal. Such cases are more common in the very young and the elderly; however, certain strains of influenza virus (like the 1918–1919 variant discussed later in this chapter) are more lethal to young adults than to the very young or old. Strains that affect young adults are believed to involve a cytokine storm—a positive feedback loop that forms between cytokine production and leukocytes. This cytokine storm produces an acute inflammatory response that leads to rapid fluid accumulation in the lungs, culminating in pulmonary failure. In such cases, the ability to mount a vigorous immune response is actually detrimental to the patient. The very young and very old are less susceptible to this effect because their immune systems are less robust.

A complication of influenza that occurs primarily in children and teenagers is **Reye syndrome**. This sequela causes swelling in the liver and brain, and may progress to neurological damage, coma, or death. Reye syndrome may follow other viral infections, like chickenpox, and has been associated with the use of aspirin. For this reason, the CDC and other agencies recommend that aspirin and products containing aspirin never be used to treat viral illnesses in children younger than age 19 years.¹⁹

18 Centers for Disease Control and Prevention. “Estimating Seasonal Influenza-Associated Deaths in the United States: CDC Study Confirms Variability of Flu.” 2016. http://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm. Accessed July 6, 2016.

19 ED Belay et al. “Reye’s Syndrome in the United States From 1981 Through 1997.” *New England Journal of Medicine* 340 no. 18 (1999):1377–1382.

The influenza virus is primarily transmitted by direct contact and inhalation of aerosols. The RNA genome of this virus exists as seven or eight segments, each coated with ribonucleoprotein and encoding one or two specific viral proteins. The influenza virus is surrounded by a lipid membrane envelope, and two of the main antigens of the influenza virus are the spike proteins hemagglutinin (H) and neuraminidase (N), as shown in [Figure 22.17](#). These spike proteins play important roles in the viral infectious cycle.




Figure 22.17 The illustration shows the structure of an influenza virus. The viral envelope is studded with copies of the proteins neuraminidase and hemagglutinin, and surrounds the individual seven or eight RNA genome segments. (credit: modification of work by Dan Higgins, Centers for Disease Control and Prevention)

Following inhalation, the influenza virus uses the hemagglutinin protein to bind to sialic acid receptors on host respiratory epithelial cells. This facilitates endocytosis of the viral particle. Once inside the host cell, the negative strand viral RNA is replicated by the viral RNA polymerase to form mRNA, which is translated by the host to produce viral proteins. Additional viral RNA molecules are transcribed to produce viral genomic RNA, which assemble with viral proteins to form mature virions. Release of the virions from the host cell is facilitated by viral neuraminidase, which cleaves sialic-acid receptors to allow progeny viruses to make a clean exit when budding from an infected cell.

There are three genetically related influenza viruses, called A, B, and C. The influenza A viruses have different subtypes based on the structure of their hemagglutinin and neuraminidase proteins. There are currently 18 known subtypes of hemagglutinin and 11 known subtypes of neuraminidase. Influenza viruses are serologically characterized by the type of H and N proteins that they possess. Of the nearly 200 different combinations of H and N, only a few, such as the H1N1 strain, are associated with human disease. The influenza viruses A, B, and C make up three of the five major groups of orthomyxoviruses. The differences between the three types of influenza are summarized in [Table 22.3](#). The most virulent group is the influenza A viruses, which cause seasonal pandemics of influenza each year. Influenza A virus can infect a variety of animals, including pigs, horses, birds, and even whales and dolphins. Influenza B virus is less virulent and is sometimes associated with epidemic outbreaks. Influenza C virus generally produces the mildest disease symptoms and is rarely connected with epidemics. Neither influenza B virus nor influenza C virus has significant animal reservoirs.

The Three Major Groups of Influenza Viruses

	Influenza A virus	Influenza B virus	Influenza C virus
Severity	Severe	Moderate	Mild
Animal reservoir	Yes	No	No

The Three Major Groups of Influenza Viruses

	Influenza A virus	Influenza B virus	Influenza C virus
Genome segments	8	8	7
Population spread	Epidemic and pandemic	Epidemic	Sporadic
Antigenic variation	Shift/drift	Drift	Drift

Table 22.3

Influenza virus infections elicit a strong immune response, particularly to the hemagglutinin protein, which would protect the individual if they encountered the same virus. Unfortunately, the antigenic properties of the virus change relatively rapidly, so new strains are evolving that immune systems previously challenged by influenza virus cannot recognize. When an influenza virus gains a new hemagglutinin or neuraminidase type, it is able to evade the host's immune response and be successfully transmitted, often leading to an epidemic.

There are two mechanisms by which these evolutionary changes may occur. The mechanisms of antigen drift and antigenic shift for influenza virus have been described in [Virulence Factors of Bacterial and Viral Pathogens](#). Of these two genetic processes, it is viruses produced by antigenic shift that have the potential to be extremely virulent because individuals previously infected by other strains are unlikely to produce any protective immune response against these novel variants.

The most lethal influenza pandemic in recorded history occurred from 1918 through 1919. Near the end of World War I, an antigenic shift involving the recombination of avian and human viruses is thought to have produced a new H1N1 virus. This strain rapidly spread worldwide and is commonly claimed to have killed as many as 40 million to 50 million people—more than double the number killed in the war. Although referred to as the Spanish flu, this disease is thought to have originated in the United States. Regardless of its source, the conditions of World War I greatly contributed to the spread of this disease. Crowding, poor sanitation, and rapid mobilization of large numbers of personnel and animals facilitated the dissemination of the new virus once it appeared.

Several of the most important influenza pandemics of modern times have been associated with antigenic shifts. A few of these are summarized in [Table 22.4](#).

Historical Influenza Outbreaks^{20 21 22}

Years	Common Name	Serotype	Estimated Number of Deaths
1918–1919	Spanish flu	H1N1	20,000,000–40,000,000
1957–1958	Asian flu	N2N2	1,000,000–2,000,000
1968–1969	Hong Kong flu	H3N2	1,000,000–3,000,000
2009–2010	Swine flu	H1N1/09	152,000–575,000

Table 22.4

20 CE Mills et al. "Transmissibility of 1918 Pandemic Influenza." *Nature* 432, no. 7019 (2004):904–906.

21 E. Tognotti. "Influenza Pandemics: A Historical Retrospect." *Journal of Infection in Developing Countries* 3, no. 5 (2009):331–334.

22 FS Dawood et al. "Estimated Global Mortality Associated with the First 12 Months of 2009 Pandemic Influenza A H1N1 Virus

Laboratory diagnosis of influenza is typically performed using a variety of RIDTs. These tests are inoculated by point-of-care personnel and give results within 15–20 minutes. Unfortunately, these tests have variable sensitivity and commonly yield false-negative results. Other tests include hemagglutination of erythrocytes (due to hemagglutinin action) or complement fixation. Patient serum antibodies against influenza viruses can also be detected in blood samples. Because influenza is self-limiting disease, diagnosis through these more time-consuming and expensive methods is not typically used.

Three drugs that inhibit influenza neuraminidase activity are available: inhaled zanamivir, oral oseltamivir, and intravenous peramivir. If taken at the onset of symptoms, these drugs can shorten the course of the disease. These drugs are thought to impair the ability of the virus to efficiently exit infected host cells. A more effective means of controlling influenza outbreaks, though, is vaccination. Every year, new influenza vaccines are developed to be effective against the strains expected to be predominant. This is determined in February by a review of the dominant strains around the world from a network of reporting sites; their reports are used to generate a recommendation for the vaccine combination for the following winter in the northern hemisphere. In September, a similar recommendation is made for the winter in the southern hemisphere.²³ These recommendations are used by vaccine manufacturers to formulate each year's vaccine. In most cases, three or four viruses are selected—the two most prevalent influenza A strains and one or two influenza B strains. The chosen strains are typically cultivated in eggs and used to produce either an inactivated or a live attenuated vaccine (e.g., FluMist). For individuals 18 years or older with an allergy to egg products, a recombinant egg-free trivalent vaccine is available. Most of the influenza vaccines over the past decade have had an effectiveness of about 50%.²⁴

Case in Point

Flu Pandemic

During the spring of 2013, a new strain of H7N9 influenza was reported in China. A total of 132 people were infected. Of those infected, 44 (33%) died. A genetic analysis of the virus suggested that this strain arose from the reassortment of three different influenza viruses: a domestic duck H7N3 virus, a wild bird H7N9 virus, and a domestic poultry H9N2 virus. The virus was detected in the Chinese domestic bird flocks and contact with this reservoir is thought to have been the primary source of infection. This strain of influenza was not able to spread from person to person. Therefore, the disease did not become a global problem. This case does, though, illustrate the potential threat that influenza still represents. If a strain like the H7N9 virus were to undergo another antigenic shift, it could become more communicable in the human population. With a mortality rate of 33%, such a pandemic would be disastrous. For this reason, organizations like the World Health Organization and the Centers for Disease Control and Prevention keep all known influenza outbreaks under constant surveillance.

✓ CHECK YOUR UNDERSTANDING

- Compare the severity of the three types of influenza viruses.
- Why must new influenza vaccines be developed each year?

Viral Pneumonia

Viruses cause fewer cases of pneumonia than bacteria; however, several viruses can lead to pneumonia in children and the elderly. The most common sources of viral pneumonia are adenoviruses, influenza viruses, parainfluenza viruses, and respiratory syncytial viruses. The signs and symptoms produced by these viruses

Circulation: A Modelling Study." *The Lancet Infectious Diseases* 12, no. 9 (2012):687–695.

23 World Health Organization. "WHO Report on Global Surveillance of Epidemic-Prone Infectious Diseases." 2000. <http://www.who.int/csr/resources/publications/surveillance/Influenza.pdf>. Accessed July 6, 2016.

24 Centers of Disease Control and Prevention. "Vaccine Effectiveness - How Well Does the Flu Vaccine Work?" 2016. <http://www.cdc.gov/flu/about/qa/vaccineeffect.htm>. Accessed July 6, 2016.

can range from mild cold-like symptoms to severe cases of pneumonia, depending on the virulence of the virus strain and the strength of the host defenses of the infected individual. Occasionally, infections can result in otitis media.

Respiratory syncytial virus (RSV) infections are fairly common in infants; most people have been infected by the age of 2 years. During infection, a viral surface protein causes host cells to fuse and form multinucleated giant cells called **syncytia**. There are no specific antiviral therapies or vaccines available for viral pneumonia. In adults, these infections are self-limiting, resemble the common cold, and tend to resolve uneventfully within 1 or 2 weeks. Infections in infants, however, can be life-threatening. RSV is highly contagious and can be spread through respiratory droplets from coughing and sneezing. RSV can also survive for a long time on environmental surfaces and, thus, be transmitted indirectly via fomites.

✓ CHECK YOUR UNDERSTANDING

- Who is most likely to contract viral pneumonia?
- What is the recommended treatment for viral pneumonia?

SARS and MERS

Severe acute respiratory syndrome (**SARS**) and Middle East respiratory syndrome (**MERS**) are two acute respiratory infections caused by coronaviruses. In both cases, these are thought to be zoonotic infections. Bats and civet cats are thought to have been the reservoirs for SARS; camels seem to be the reservoir for MERS.

SARS originated in southern China in the winter of 2002 and rapidly spread to 37 countries. Within about 1 year, more than 8,000 people experienced influenza-like symptoms and nearly 800 people died. The rapid spread and severity of these infections caused grave concern at the time. However, the outbreak was controlled in 2003 and no further cases of SARS have been recorded since 2004.²⁵ Signs and symptoms of SARS include high fever, headache, body aches, and cough, and most patients will develop pneumonia.

MERS was first reported in Saudi Arabia in 2013. Although some infected individuals will be asymptomatic or have mild cold-like symptoms, most will develop a high fever, aches, cough and a severe respiratory infection that can progress to pneumonia. As of 2015, over 1,300 people in 27 countries have been infected. About 500 people have died. There are no specific treatments for either MERS or SARS. In addition, no vaccines are currently available. Several recombinant vaccines, however, are being developed.

✓ CHECK YOUR UNDERSTANDING

- What is the cause of SARS?
- What are the signs and symptoms of MERS?

Viral Respiratory Diseases Causing Skin Rashes

Measles, rubella (German measles), and chickenpox are three important viral diseases often associated with skin rashes. However, their symptoms are systemic, and because their portal of entry is the respiratory tract, they can be considered respiratory infections.

Measles (Rubeola)

The measles virus (MeV) causes the highly contagious disease **measles**, also known as rubeola, which is a major cause of childhood mortality worldwide. Although vaccination efforts have greatly reduced the incidence of measles in much of the world, epidemics are still common in unvaccinated populations in certain countries.²⁶

25 Y. Huang. "The SARS Epidemic and Its Aftermath in China: A Political Perspective." In *Learning from SARS: Preparing for the Next Disease Outbreak*. Edited by S. Knobler et al. Washington, DC: National Academies Press; 2004. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK92479/>

26 Centers for Disease Control and Prevention. "Global Health - Measles, Rubella, and CRS, Eliminating Measles, Rubella &

The measles virus is a single-stranded, negative-strand RNA virus and, like the influenza virus, it possesses an envelope with spikes of embedded hemagglutinin. The infection is spread by direct contact with infectious secretions or inhalation of airborne droplets spread by breathing, coughing, or sneezing. Measles is initially characterized by a high fever, conjunctivitis, and a sore throat. The virus then moves systemically through the bloodstream and causes a characteristic rash. The measles rash initially forms on the face and later spreads to the extremities. The red, raised macular rash will eventually become confluent and can last for several days. At the same time, extremely high fevers (higher than 40.6 °C [105 °F]) can occur. Another diagnostic sign of measles infections is **Koplik's spots**, white spots that form on the inner lining of inflamed cheek tissues (Figure 22.18).




Figure 22.18 (a and b) Measles typically presents as a raised macular rash that begins on the face and spreads to the extremities. (c) Koplik's spots on the oral mucosa are also characteristic of measles. (d) A thin-section transmission electron micrograph of a measles virion. (credit a: a. Betty G. Partin /CDC.; b, c: modification of work by Centers for Disease Control and Prevention)

Although measles is usually self-limiting, it can lead to pneumonia, encephalitis, and death. In addition, the inhibition of immune system cells by the measles virus predisposes patients to secondary infections. In severe infections with highly virulent strains, measles fatality rates can be as high as 10% to 15%. There were more than 145,000 measles deaths (mostly young children) worldwide in 2013.²⁷

The preliminary diagnosis of measles is typically based on the appearance of the rash and Koplik's spots. Hemagglutination inhibition tests and serological tests may be used to confirm measles infections in low-prevalence settings.

There are no effective treatments for measles. Vaccination is widespread in developed countries as part of the measles, mumps, and rubella (MMR) vaccine. As a result, there are typically fewer than 200 cases of measles in the United States annually.²⁸ When it is seen, it is often associated with children who have not been vaccinated.

Congenital Rubella Syndrome (CRS) Worldwide." 2015. <http://www.cdc.gov/globalhealth/measles/>. Accessed July 7, 2016.

27 World Health Organization. "Measles Factsheet." 2016. <http://www.who.int/mediacentre/factsheets/fs286/en/>. Accessed July 7, 2016.

28 Centers for Disease Control and Prevention. "Measles Cases and Outbreaks." 2016. <http://www.cdc.gov/measles/cases-outbreaks.html>. Accessed July 7, 2016.



MICRO CONNECTIONS

Preventable Measles Outbreaks

In December 2014, a measles epidemic began at Disneyland in southern California. Within just 4 months, this outbreak affected 134 people in 24 states.²⁹ Characterization of the virus suggests that an unidentified infected individual brought the disease to the United States from the Philippines, where a similar virus had sickened more than 58,000 people and killed 110.³⁰ Measles is highly communicable, and its spread at Disneyland may have been facilitated by the low vaccination rate in some communities in California.³¹

Several factors could conceivably lead to a strong comeback of measles in the U.S. Measles is still an epidemic disease in many locations worldwide. Air travel enables infected individuals to rapidly translocate these infections globally. Compounding this problem, low vaccination rates in some local areas in the United States (such as in Amish communities) provide populations of susceptible hosts for the virus to establish itself. Finally, measles has been a low-prevalence infection in the U.S. for some time. As a consequence, physicians are not as likely to recognize the initial symptoms and make accurate diagnoses. Until vaccination rates become high enough to ensure herd immunity, measles is likely to be an ongoing problem in the United States.

Rubella (German Measles)

Rubella, or the German measles, is a relatively mild viral disease that produces a rash somewhat like that caused by the measles, even though the two diseases are unrelated. The rubella virus is an enveloped RNA virus that can be found in the respiratory tract. It is transmitted from person to person in aerosols produced by coughing or sneezing. Nearly half of all infected people remain asymptomatic. However, the virus is shed and spread by asymptomatic carriers. Like rubeola, **rubella** begins with a facial rash that spreads to the extremities (Figure 22.19). However, the rash is less intense, shorter lived (2–3 days), not associated with Koplik's spots, and the resulting fever is lower (101 °F [38.3 °C]).

Congenital rubella syndrome is the most severe clinical complication of the German measles. This occurs if a woman is infected with rubella during pregnancy. The rubella virus is **teratogenic**, meaning it can cause developmental defects if it crosses the placenta during pregnancy. There is a very high incidence of stillbirth, spontaneous abortion, or congenital birth defects if the mother is infected before 11 weeks of pregnancy and 35% if she is infected between weeks 13–16; after this time the incidence is low.³² For this reason, prenatal screening for rubella is commonly practiced in the United States. Postnatal infections are usually self-limiting and rarely cause severe complications.

Like measles, the preliminary diagnosis of rubella is based on the patient's history, vaccination records, and the appearance of the rash. The diagnosis can be confirmed by hemagglutinin inhibition assays and a variety of other immunological techniques. There are no antiviral therapies for rubella, but an effective vaccine (MMR) is widely available. Vaccination efforts have essentially eliminated rubella in the United States; fewer than a dozen cases are reported in a typical year.

29 Ibid.

30 World Health Organization. "Measles-Rubella Bulletin." Manila, Philippines; Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization; 9 no. 1 (2015). <http://www.wpro.who.int/immunization/documents/mrbulletinvol9issue1.pdf>

31 M. Bloch et al. "Vaccination Rates for Every Kindergartener in California." *The New York Times* February 6, 2015. http://www.nytimes.com/interactive/2015/02/06/us/california-measles-vaccines-map.html?_r=1. Accessed July 7, 2016.

32 E. Miller et al. "Consequences of Confirmed Maternal Rubella at Successive Stages of Pregnancy." *The Lancet* 320, no. 8302 (1982):781–784.




Figure 22.19 (a) This photograph shows the appearance of the German measles (rubella) rash. Note that this is less intense than the rash of measles and the lesions are not confluent. (b) This transmission electron micrograph shows rubella virus virions just budding from a host cell. (credit a, b: modification of work by Centers for Disease Control and Prevention)

Chickenpox and Shingles

Chickenpox, also known as varicella, was once a common viral childhood disease. The causative agent of **chickenpox**, the varicella-zoster virus, is a member of the herpesvirus family. In children, the disease is mild and self-limiting, and is easily transmitted by direct contact or inhalation of material from the skin lesions. In adults, however, chickenpox infections can be much more severe and can lead to pneumonia and birth defects in the case of infected pregnant women. Reye syndrome, mentioned earlier in this chapter, is also a serious complication associated with chickenpox, generally in children.

Once infected, most individuals acquire a lifetime immunity to future chickenpox outbreaks. For this reason, parents once held “chickenpox parties” for their children. At these events, uninfected children were intentionally exposed to an infected individual so they would contract the disease earlier in life, when the incidence of complications is very low, rather than risk a more severe infection later.

After the initial viral exposure, chickenpox has an incubation period of about 2 weeks. The initial infection of the respiratory tract leads to viremia and eventually produces fever and chills. A pustular rash then develops on the face, progresses to the trunk, and then the extremities, although most form on the trunk ([Figure 22.20](#)). Eventually, the lesions burst and form a crusty scab. Individuals with chickenpox are infectious from about 2 days before the outbreak of the rash until all the lesions have scabbed over.




Figure 22.20 (a) and (b) The characteristic appearance of the pustular chickenpox rash is concentrated on the trunk region. (c) This transmission electron micrograph shows a viroid of human herpesvirus 3, the virus that causes chickenpox in children and shingles when it is reactivated in adults. Credit b: John Noble/CDC. c: modification of work by Centers for Disease Control and Prevention)

Like other herpesviruses, the varicella-zoster virus can become dormant in nerve cells. While the pustular vesicles are developing, the virus moves along sensory nerves to the dorsal ganglia in the spinal cord. Once there, the varicella-zoster virus can remain latent for decades. These dormant viruses may be reactivated later in life by a variety of stimuli, including stress, aging, and immunosuppression. Once reactivated, the virus moves along sensory nerves to the skin of the face or trunk. This results in the production of the painful lesions in a condition known as **shingles** (Figure 22.21). These symptoms generally last for 2–6 weeks, and may recur more than once. Postherpetic neuralgia, pain signals sent from damaged nerves long after the other symptoms have subsided, is also possible. In addition, the virus can spread to other organs in immunocompromised individuals. A person with shingles lesions can transmit the virus to a nonimmune contact, and the newly infected individual would develop chickenpox as the primary infection. Shingles cannot be transmitted from one person to another.

The primary diagnosis of chickenpox in children is mainly based on the presentation of a pustular rash of the trunk. Serological and PCR-based tests are available to confirm the initial diagnosis. Treatment for chickenpox infections in children is usually not required. In patients with shingles, acyclovir treatment can often reduce the severity and length of symptoms, and diminish the risk of postherpetic neuralgia. An effective vaccine is now available for chickenpox. A vaccine is also available for adults older than 60 years who were infected with chickenpox in their youth. This vaccine reduces the likelihood of a shingles outbreak by boosting the immune defenses that are keeping the latent infection in check and preventing reactivation.




Figure 22.21 (a and b) An individual suffering from shingles. (c) The rash is formed because of the reactivation of a varicella-zoster infection that was initially contracted in childhood. (credit a: modification of work by National Institute of Allergy and Infectious Diseases (NIAID); credit b: Robert E. Sumpter/CDC.; credit c: modification of work by Centers for Disease Control and Prevention)

✓ CHECK YOUR UNDERSTANDING

- Why does measles often lead to secondary infections?
- What signs or symptoms would distinguish rubella and measles?
- Why can chickenpox lead to shingles later in life?

Eye on Ethics

Smallpox Stockpiles

Smallpox has probably killed more humans than any other infectious disease, with the possible exception of tuberculosis. This disease, caused by the variola major virus, is transmitted by inhalation of viral particles shed from lesions in the throat. The smallpox virus spreads systemically in the bloodstream and produces a pustular skin rash. Historical epidemics of smallpox had fatality rates of 50% or greater in susceptible populations. Concerted worldwide vaccination efforts eradicated smallpox from the general population in 1977. This was the first microbial disease in history to be eradicated, a feat made possible by the fact that the only reservoir for the smallpox virus is infected humans.

Although the virus is no longer present in the wild, laboratory samples of the virus still exist in the United States and Russia.³³ The question is, why do these samples still exist? Some claim that these stocks should be maintained for research purposes. Should the smallpox virus ever reappear, they say, we would need access to such stocks for development of vaccines and treatments. Concerns about a re-emergence of the virus are not totally unfounded. Although there are no living reservoirs of the virus, there is always the possibility that smallpox could re-emerge from mummified human bodies or human remains preserved in permafrost. It is also possible that there are as-yet undiscovered samples of the virus in other locations around the world. An example of such "lost" samples was discovered in a drawer in a Food and Drug Administration lab in Maryland.³⁴ If an outbreak from such a source were to occur, it could lead to uncontrolled epidemics, since the population is largely unvaccinated now.

Critics of this argument, including many research scientists and the World Health Organization, claim that there is no longer any rational argument for keeping the samples. They view the "re-emergence scenarios" as a thinly veiled pretense for harboring biological weapons. These scenarios, they say, are less probable than an intentional reintroduction of the virus from militarized stocks by humans. Furthermore, they point out that if we needed to research smallpox in the future, we could rebuild the virus from its DNA sequence.

What do you think? Are there legitimate arguments for maintaining stockpiles of smallpox, or should all forms of this deadly disease be eradicated?



Disease Profile

Viral Infections of the Respiratory Tract

Many viruses are capable of entering and causing disease in the respiratory system, and a number are able to spread beyond the respiratory system to cause systemic infections. Most of these infections are highly contagious and, with a few exceptions, antimicrobial drugs are not effective for treatment. Although some of these infections are self-limiting, others can have serious or fatal complications. Effective vaccines have been developed for several of these diseases, as summarized in [Figure 22.22](#).

33 Centers for Disease Control and Prevention. "CDC Media Statement on Newly Discovered Smallpox Specimens." July 8, 2014. <http://www.cdc.gov/media/releases/2014/s0708-nih.html>. Accessed on July 7, 2016.

34 Ibid.

Viral Infections of the Respiratory Tract				
Disease	Pathogen	Signs and Symptoms	Transmission	Vaccine
Chickenpox (varicella)	Varicella-zoster virus	In children, fever, chills, pustular rash of lesions that burst and form crusty scabs; in adults, more severe symptoms and complications (e.g., pneumonia)	Highly contagious via contact with aerosols, particles, or droplets from infected individual's blisters or respiratory secretions	Varicella (chickenpox) vaccine
Common cold	Rhinoviruses, adenoviruses, coronaviruses, others	Runny nose, congestion, sore throat, sneezing, headaches and muscle aches; may lead to otitis media, pharyngitis, laryngitis	Highly contagious via contact with respiratory secretions or inhalation of droplets or aerosols	None
Influenza	Influenza viruses A, B, C	Fever, chills, headaches, body aches, fatigue; may lead to pneumonia or complications such as Reye syndrome. Highly virulent strains may cause lethal complications	Highly contagious between humans via contact with respiratory secretions or inhalation of droplets or aerosols. Influenza A virus can be transmitted from animal reservoirs.	Vaccines developed yearly against most prevalent strains
Measles	Measles virus (MeV)	High fever, conjunctivitis, sore throat, macular rash becoming confluent, Koplik's spots on oral mucosa; in severe cases, can lead to fatal pneumonia or encephalitis, especially in children	Highly contagious via contact with respiratory secretions, skin rash, or eye secretions of infected individual	MMR
MERS	Middle East respiratory syndrome coronavirus (MERS-CoV)	Fever, cough, shortness of breath; in some cases, complications such as pneumonia and kidney failure; can be fatal	Contact with respiratory secretions or inhalation of droplets or aerosols	None
Rubella (German measles)	Rubella virus	Facial rash spreading to extremities, followed by low-grade fever, headache, conjunctivitis, cough, runny nose, swollen lymph nodes; congenital rubella may cause birth defects, miscarriage, or stillbirth	Contagious via inhalation of droplets or aerosols from infected person or asymptomatic carrier; transplacental infection from mother to fetus	MMR
SARS	SARS-associated coronavirus (SARS-CoV)	High fever, headache, body aches, dry cough, pneumonia; can be fatal	Contact with respiratory secretions or inhalation of droplets or aerosols	None
Shingles	Varicella-zoster virus	Painful lesions on face or trunk lasting several weeks; may cause postherpetic neuralgia (chronic pain) or spread to organs in severe cases	Nontransmissible; occurs when dormant virus is reactivated, generally many years after initial chicken-pox infection	Herpes zoster (shingles) vaccine
Viral pneumonia	Adenoviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, others	From mild cold-like symptoms to severe pneumonia; in infants, RSV infections may be life-threatening	Highly contagious via contact with respiratory secretions or inhalation of droplets or aerosols	None

Figure 22.22

22.4 Respiratory Mycoses

Learning Objectives

By the end of this section, you will be able to:

- Identify the most common fungi that can cause infections of the respiratory tract
- Compare the major characteristics of specific fungal diseases of the respiratory tract

Fungal pathogens are ubiquitous in the environment. Serological studies have demonstrated that most people

have been exposed to fungal respiratory pathogens during their lives. Yet symptomatic infections by these microbes are rare in healthy individuals. This demonstrates the efficacy of the defenses of our respiratory system. In this section, we will examine some of the fungi that can cause respiratory infections.

Histoplasmosis

Histoplasmosis is a fungal disease of the respiratory system and most commonly occurs in the Mississippi Valley of the United States and in parts of Central and South America, Africa, Asia, and Australia. The causative agent, *Histoplasma capsulatum*, is a dimorphic fungus. This microbe grows as a filamentous mold in the environment but occurs as a budding yeast during human infections. The primary reservoir for this pathogen is soil, particularly in locations rich in bat or bird feces.

Histoplasmosis is acquired by inhaling microconidial spores in the air; this disease is not transmitted from human to human. The incidence of **histoplasmosis** exposure is high in endemic areas, with 60%–90% of the population having anti-*Histoplasma* antibodies, depending on location;³⁵ however, relatively few individuals exposed to the fungus actually experience symptoms. Those most likely to be affected are the very young, the elderly, and immunocompromised people.

In many ways, the course of this disease is similar to that of tuberculosis. Following inhalation, the spores enter the lungs and are phagocytized by alveolar macrophages. The fungal cells then survive and multiply within these phagocytes (see [Figure 5.26](#)). Focal infections cause the formation of granulomatous lesions, which can lead to calcifications that resemble the Ghon complexes of tuberculosis, even in asymptomatic cases. Also like tuberculosis, histoplasmosis can become chronic and reactivation can occur, along with dissemination to other areas of the body (e.g., the liver or spleen).

Signs and symptoms of pulmonary histoplasmosis include fever, headache, and weakness with some chest discomfort. The initial diagnosis is often based on chest radiographs and cultures grown on fungal selective media like Sabouraud's dextrose agar. Direct fluorescence antibody staining and Giemsa staining can also be used to detect this pathogen. In addition, serological tests including a complement fixation assay and histoplasmin sensitivity can be used to confirm the diagnosis. In most cases, these infections are self-limiting and antifungal therapy is not required. However, in disseminated disease, the antifungal agents amphotericin B and ketoconazole are effective; itraconazole may be effective in immunocompromised patients, in whom the disease can be more serious.

CHECK YOUR UNDERSTANDING

- In what environments is one more likely to be infected with histoplasmosis?
- Identify at least two similarities between histoplasmosis and tuberculosis.

Coccidioidomycosis

Infection by the dimorphic fungus *Coccidioides immitis* causes **coccidioidomycosis**. Because the microbe is endemic to the San Joaquin Valley of California, the disease is sometimes referred to as Valley fever. A related species that causes similar infections is found in semi-arid and arid regions of the southwestern United States, Mexico, and Central and South America.³⁶

Like histoplasmosis, coccidioidomycosis is acquired by inhaling fungal spores—in this case, arthrospores formed by hyphal fragmentation. Once in the body, the fungus differentiates into spherules that are filled with endospores. Most *C. immitis* infections are asymptomatic and self-limiting. However, the infection can be very serious for immunocompromised patients. The endospores may be transported in the blood, disseminating the infection and leading to the formation of granulomatous lesions on the face and nose ([Figure 22.23](#)). In severe cases, other major organs can become infected, leading to serious complications such as fatal meningitis.

35 NE Manos et al. "Geographic Variation in the Prevalence of Histoplasmin Sensitivity." *Dis Chest* 29, no. 6 (1956):649–668.

36 DR Hospenthal. "Coccidioidomycosis." Medscape. 2015. <http://emedicine.medscape.com/article/215978-overview>. Accessed July 7, 2016.

Coccidioidomycosis can be diagnosed by culturing clinical samples. *C. immitis* readily grows on laboratory fungal media, such as Sabouraud's dextrose agar, at 35 °C (95 °F). Culturing the fungus, however, is rather dangerous. *C. immitis* is one of the most infectious fungal pathogens known and is capable of causing laboratory-acquired infections. Indeed, until 2012, this organism was considered a “select agent” of bioterrorism and classified as a BSL-3 microbe. Serological tests for antibody production are more often used for diagnosis. Although mild cases generally do not require intervention, disseminated infections can be treated with intravenous antifungal drugs like amphotericin B.




Figure 22.23 (a) This patient has extensive facial lesions due to a disseminated *Coccidioides* infection. (b) This fluorescent micrograph depicts a spherule of *C. immitis* containing endospores. (credit a, b: modification of work by Centers for Disease Control and Prevention)

Clinical Focus

Resolution

John's negative RIDT tests do not rule out influenza, since false-negative results are common, but the *Legionella* infection still must be treated with antibiotic therapy and is the more serious condition. John's prognosis is good, provided the physician can find an antibiotic therapy to which the infection responds.

While John was undergoing treatment, three of the employees from the home improvement store also reported to the clinic with very similar symptoms. All three were older than 55 years and had *Legionella* antigen in their urine; *L. pneumophila* was also isolated from their sputum. A team from the health department was sent to the home improvement store to identify a probable source for these infections. Their investigation revealed that about 3 weeks earlier, the store's air conditioning system, which was located where the employees ate lunch, had been undergoing maintenance. *L. pneumophila* was isolated from the cooling coils of the air conditioning system and intracellular *L. pneumophila* was observed in amoebae in samples of condensed water from the cooling coils as well (Figure 22.24). The amoebae provide protection for the *Legionella* bacteria and are known to enhance their pathogenicity.³⁷

In the wake of the infections, the store ordered a comprehensive cleaning of the air conditioning system and implemented a regular maintenance program to prevent the growth of biofilms within the cooling tower. They also reviewed practices at their other facilities.

After a month of rest at home, John recovered from his infection enough to return to work, as did the other three employees of the store. However, John experienced lethargy and joint pain for more than a year after his treatment.

37 HY Lau and NJ Ashbolt. “The Role of Biofilms and Protozoa in *Legionella* Pathogenesis: Implications for Drinking Water.” *Journal of Applied Microbiology* 107 no. 2 (2009):368–378.




Figure 22.24 *Legionella pneumophila* (red intracellular rods) infecting amoebae from a contaminated water sample. (credit: modification of work by Centers for Disease Control and Prevention)

Go back to the [previous Clinical Focus box](#).

Blastomycosis

Blastomycosis is a rare disease caused by another dimorphic fungus, *Blastomyces dermatitidis*. Like *Histoplasma* and *Coccidioides*, *Blastomyces* uses the soil as a reservoir, and fungal spores can be inhaled from disturbed soil. The pulmonary form of **blastomycosis** generally causes mild flu-like symptoms and is self-limiting. It can, however, become disseminated in immunocompromised people, leading to chronic cutaneous disease with subcutaneous lesions on the face and hands ([Figure 22.25](#)). These skin lesions eventually become crusty and discolored and can result in deforming scars. Systemic blastomycosis is rare, but if left untreated, it is always fatal.

Preliminary diagnosis of pulmonary blastomycosis can be made by observing the characteristic budding yeast forms in sputum samples. Commercially available urine antigen tests are now also available. Additional confirmatory tests include serological assays such as immunodiffusion tests or EIA. Most cases of blastomycosis respond well to amphotericin B or ketoconazole treatments.




Figure 22.25 (a) These skin lesions are the result of disseminated cutaneous blastomycosis. (b) A differential interference contrast micrograph of *B. dermatitidis* yeast cultured on blood agar. (credit a: modification of work by Centers for Disease Control and Prevention)

LINK TO LEARNING

Watch this [profile \(https://openstax.org/l/22blastlunginf\)](https://openstax.org/l/22blastlunginf) of a blastomycosis lung infection.

Mucormycosis

A variety of fungi in the order Mucorales cause **mucormycosis**, a rare fungal disease. These include bread molds, like *Rhizopus* and *Mucor*; the most commonly associated species is *Rhizopus arrhizus (oryzae)* (see [Figure 5.28](#)). These fungi can colonize many different tissues in immunocompromised patients, but often infect the skin, sinuses, or the lungs.

Although most people are regularly exposed to the causative agents of mucormycosis, infections in healthy individuals are rare. Exposure to spores from the environment typically occurs through inhalation, but the spores can also infect the skin through a wound or the gastrointestinal tract if ingested. Respiratory mucormycosis primarily affects immunocompromised individuals, such as patients with cancer or those who have had a transplant.³⁸

After the spores are inhaled, the fungi grow by extending hyphae into the host's tissues. Infections can occur in both the upper and lower respiratory tracts. Rhinocerebral mucormycosis is an infection of the sinuses and brain; symptoms include headache, fever, facial swelling, congestion, and tissue necrosis causing black lesions in the oral cavity. Pulmonary mucormycosis is an infection of the lungs; symptoms include fever, cough, chest pain, and shortness of breath. In severe cases, infections may become disseminated and involve the central nervous system, leading to coma and death.³⁹

Diagnosing mucormycosis can be challenging. Currently, there are no serological or PCR-based tests available to identify these infections. Tissue biopsy specimens must be examined for the presence of the fungal pathogens. The causative agents, however, are often difficult to distinguish from other filamentous fungi. Infections are typically treated by the intravenous administration of amphotericin B, and superficial infections are removed by surgical debridement. Since the patients are often immunocompromised, viral and bacterial secondary infections commonly develop. Mortality rates vary depending on the site of the infection, the causative fungus, and other factors, but a recent study found an overall mortality rate of 54%.⁴⁰

CHECK YOUR UNDERSTANDING

- Compare the modes of transmission for coccidioidomycosis, blastomycosis, and mucormycosis.
 - In general, which are more serious: the pulmonary or disseminated forms of these infections?
-

Aspergillosis

Aspergillus is a common filamentous fungus found in soils and organic debris. Nearly everyone has been exposed to this mold, yet very few people become sick. In immunocompromised patients, however, *Aspergillus* may become established and cause **aspergillosis**. Inhalation of spores can lead to asthma-like allergic reactions. The symptoms commonly include shortness of breath, wheezing, coughing, runny nose, and headaches. Fungal balls, or aspergilloma, can form when hyphal colonies collect in the lungs ([Figure 22.26](#)). The fungal hyphae can invade the host tissues, leading to pulmonary hemorrhage and a bloody cough. In severe cases, the disease may progress to a disseminated form that is often fatal. Death most often results from pneumonia or brain hemorrhages.

Laboratory diagnosis typically requires chest radiographs and a microscopic examination of tissue and

38 Centers for Disease Control and Prevention. "Fungal Diseases. Definition of Mucormycosis." 2015 <http://www.cdc.gov/fungal/diseases/mucormycosis/definition.html>. Accessed July 7, 2016.

39 Centers for Disease Control and Prevention. "Fungal Diseases. Symptoms of Mucormycosis." 2015 <http://www.cdc.gov/fungal/diseases/mucormycosis/symptoms.html>. Accessed July 7, 2016.

40 MM Roden et al. "Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases." *Clinical Infectious Diseases* 41 no. 5 (2005):634–653.

respiratory fluid samples. Serological tests are available to identify *Aspergillus* antigens. In addition, a skin test can be performed to determine if the patient has been exposed to the fungus. This test is similar to the Mantoux tuberculin skin test used for tuberculosis. Aspergillosis is treated with intravenous antifungal agents, including itraconazole and voriconazole. Allergic symptoms can be managed with corticosteroids because these drugs suppress the immune system and reduce inflammation. However, in disseminated infections, corticosteroids must be discontinued to allow a protective immune response to occur.




Figure 22.26 A fungal ball can be observed in the upper lobe of the right lung in this chest radiograph of a patient with aspergilloma. (credit: modification of work by Centers for Disease Control and Prevention)

Pneumocystis Pneumonia

A type of pneumonia called ***Pneumocystis pneumonia*** (PCP) is caused by *Pneumocystis jirovecii*. Once thought to be a protozoan, this organism was formerly named *P. carinii* but it has been reclassified as a fungus and renamed based on biochemical and genetic analyses. *Pneumocystis* is a leading cause of pneumonia in patients with acquired immunodeficiency syndrome (AIDS) and can be seen in other compromised patients and premature infants. Respiratory infection leads to fever, cough, and shortness of breath. Diagnosis of these infections can be difficult. The organism is typically identified by microscopic examination of tissue and fluid samples from the lungs (Figure 22.27). A PCR-based test is available to detect *P. jirovecii* in asymptomatic patients with AIDS. The best treatment for these infections is the combination drug trimethoprim-sulfamethoxazole (TMP/SMZ). These sulfa drugs often have adverse effects, but the benefits outweigh these risks. Left untreated, PCP infections are often fatal.




Figure 22.27 A light micrograph of a smear containing *Pneumocystis jirovecii* (dark purple cells) obtained from human lung tissue and stained with toluidine blue. (credit: Centers for Disease Control and Prevention)

Cryptococcosis

Infection by the encapsulated yeast *Cryptococcus neoformans* causes **cryptococcosis**. This fungus is ubiquitous in the soil and can be isolated from bird feces. Immunocompromised people are infected by inhaling basidiospores found in aerosols. The thick polysaccharide capsule surrounding these microbes enables them to avoid clearance by the alveolar macrophage. Initial symptoms of infection include fever, fatigue, and a dry cough. In immunocompromised patients, pulmonary infections often disseminate to the brain. The resulting meningitis produces headaches, sensitivity to light, and confusion. Left untreated, such infections are often fatal. The verification code for this document is 854710

Cryptococcus infections are often diagnosed based on microscopic examination of lung tissues or cerebrospinal fluids. India ink preparations (Figure 22.28) can be used to visualize the extensive capsules that surround the yeast cells. Serological tests are also available to confirm the diagnosis. Amphotericin B, in combination with flucytosine, is typically used for the initial treatment of pulmonary infections. Amphotericin B is a broad-spectrum antifungal drug that targets fungal cell membranes. It can also adversely impact host cells and produce side effects. For this reason, clinicians must carefully balance the risks and benefits of treatments in these patients. Because it is difficult to eradicate cryptococcal infections, patients usually need to take fluconazole for up to 6 months after treatment with amphotericin B and flucytosine to clear the fungus. Cryptococcal infections are more common in immunocompromised people, such as those with AIDS. These patients typically require life-long suppressive therapy to control this fungal infection.




Figure 22.28 (a) The micrograph shows stained budding *Cryptococcus* yeast cells from the lungs of a patient with AIDS. (b) The large capsule of *Cryptococcus neoformans* is visible in this negative stain micrograph. (credit a, b: modification of work by Centers for Disease Control and Prevention)

✓ CHECK YOUR UNDERSTANDING

- What populations are most at risk for developing *Pneumocystis* pneumonia or cryptococcosis?
- Why are these infections fatal if left untreated?

Disease Profile

Fungal Diseases of the Respiratory Tract

Most respiratory mycoses are caused by fungi that inhabit the environment. Such infections are generally transmitted via inhalation of fungal spores and cannot be transmitted between humans. In addition, healthy people are generally not susceptible to infection even when exposed; the fungi are only virulent enough to establish infection in patients with HIV, AIDS, or another condition that compromises the immune defenses. Figure 22.29 summarizes the features of important respiratory mycoses.

Fungal Infections of the Respiratory Tract				
Disease	Pathogen	Signs and Symptoms	Diagnostic Tests	Antimicrobial Drugs
Aspergillosis	<i>Aspergillus fumigatus</i>	Shortness of breath, wheezing, coughing, runny nose, headaches; formation of aspergillomas causing severe pneumonia and pulmonary or brain hemorrhages; can be fatal	Chest radiograph, skin test, microscopic observation of sputum samples	Itraconazole, voriconazole
Blastomycosis	<i>Blastomyces dermatitidis</i>	Fever, chills, cough, headache, fatigue, chest pain, body aches; in disseminated infections, chronic, crusted lesions on face and hands with permanent scarring; can be fatal	Microscopic observation of sputum samples; urine antigen test; EIA	Amphotericin B, ketoconazole
Coccidioidomycosis (Valley fever)	<i>Coccidioides immitis</i>	Granulomatous lesions on face and nose; may spread to organs or brain, causing fatal meningitis	Culture (in BSL-3 lab only), serological antibody tests	Amphotericin B
Cryptococcosis	<i>Cryptococcus neoformans</i>	Fever, cough, shortness of breath; can cause fatal meningitis if disseminated to brain	Microscopic examination of lung tissue or cerebrospinal fluid	Amphotericin B, fluconazole, flucytosine
Histoplasmosis	<i>Histoplasma capsulatum</i>	Fever, headache, weakness, chest pain, lesions on lungs	Chest radiograph, culture, direct fluorescence antibody staining, complement fixation assay, histoplasmin sensitivity test	Amphotericin B, ketoconazole, itraconazole
Mucormycosis	<i>Rhizopus arrhizus</i> , other <i>Rhizopus</i> spp., <i>Mucor</i> spp.	Headache, fever, facial swelling, congestion, black lesions in oral cavity, cough, chest pain, shortness of breath; often fatal	Microscopic examination of tissue biopsy specimens	Amphotericin B
<i>Pneumocystis</i> pneumonia (PCP)	<i>Pneumocystis jirovecii</i>	Fever, cough, shortness of breath; can be fatal if untreated	Microscopic examination of lung tissue and fluid, PCR	Trimethoprim-sulfamethoxazole

Figure 22.29

SUMMARY

22.1 Anatomy and Normal Microbiota of the Respiratory Tract

- The respiratory tract is divided into upper and lower regions at the **epiglottis**.
- Air enters the upper respiratory tract through the **nasal cavity** and mouth, which both lead to the **pharynx**. The lower respiratory tract extends from the **larynx** into the **trachea** before branching into the **bronchi**, which divide further to form the **bronchioles**, which terminate in **alveoli**, where gas exchange occurs.
- The upper respiratory tract is colonized by an extensive and diverse normal microbiota, many of which are potential pathogens. Few microbial inhabitants have been found in the lower respiratory tract, and these may be transients.
- Members of the normal microbiota may cause opportunistic infections, using a variety of strategies to overcome the innate nonspecific defenses (including the mucociliary escalator) and adaptive specific defenses of the respiratory system.
- Effective vaccines are available for many common respiratory pathogens, both bacterial and viral.
- Most respiratory infections result in inflammation of the infected tissues; these conditions are given names ending in *-itis*, such as **rhinitis**, **sinusitis**, **otitis**, **pharyngitis**, and **bronchitis**.

22.2 Bacterial Infections of the Respiratory Tract

- A wide variety of bacteria can cause respiratory diseases; most are treatable with antibiotics or preventable with vaccines.
- *Streptococcus pyogenes* causes **strep throat**, an infection of the pharynx that also causes high fever and can lead to **scarlet fever**, **acute rheumatic fever**, and **acute glomerulonephritis**.
- **Acute otitis media** is an infection of the middle ear that may be caused by several bacteria, including *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. The infection can block the eustachian tubes, leading to **otitis media with effusion**.
- **Diphtheria**, caused by *Corynebacterium diphtheriae*, is now a rare disease because of

widespread vaccination. The bacteria produce exotoxins that kill cells in the pharynx, leading to the formation of a **pseudomembrane**; and damage other parts of the body.

- **Bacterial pneumonia** results from infections that cause inflammation and fluid accumulation in the alveoli. It is most commonly caused by *S. pneumoniae* or *H. influenzae*. The former is commonly multidrug resistant.
- **Mycoplasma pneumonia** results from infection by *Mycoplasma pneumoniae*; it can spread quickly, but the disease is mild and self-limiting.
- **Chlamydial pneumonia** can be caused by three pathogens that are obligate intracellular parasites. *Chlamydomphila pneumoniae* is typically transmitted from an infected person, whereas *C. psittaci* is typically transmitted from an infected bird. *Chlamydia trachomatis*, may cause pneumonia in infants.
- Several other bacteria can cause pneumonia in immunocompromised individuals and those with cystic fibrosis.
- **Tuberculosis** is caused by *Mycobacterium tuberculosis*. Infection leads to the production of protective **tubercles** in the alveoli and calcified **Ghon complexes** that can harbor the bacteria for a long time. Antibiotic-resistant forms are common and treatment is typically long term.
- **Pertussis** is caused by *Bordetella pertussis*. Mucus accumulation in the lungs leads to prolonged severe coughing episodes (whooping cough) that facilitate transmission. Despite an available vaccine, outbreaks are still common.
- **Legionnaires disease** is caused by infection from environmental reservoirs of the *Legionella pneumophila* bacterium. The bacterium is endocytic within macrophages and infection can lead to pneumonia, particularly among immunocompromised individuals.
- **Q fever** is caused by *Coxiella burnetii*, whose primary hosts are domesticated mammals (zoonotic disease). It causes pneumonia primarily in farm workers and can lead to serious complications, such as endocarditis.

22.3 Viral Infections of the Respiratory Tract

- Viruses cause respiratory tract infections more frequently than bacteria, and most viral infections lead to mild symptoms.
- The **common cold** can be caused by more than

200 viruses, typically rhinoviruses, coronaviruses, and adenoviruses, transmitted by direct contact, aerosols, or environmental surfaces.

- Due to its ability to rapidly mutate through **antigenic drift** and **antigenic shift**, **influenza** remains an important threat to human health. Two new influenza vaccines are developed annually.
- Several viral infections, including **respiratory syncytial virus** infections, which frequently occur in the very young, can begin with mild symptoms before progressing to viral pneumonia.
- **SARS** and **MERS** are acute respiratory infections caused by coronaviruses, and both appear to originate in animals. SARS has not been seen in the human population since 2004 but had a high mortality rate during its outbreak. MERS also has a high mortality rate and continues to appear in human populations.
- **Measles**, **rubella**, and **chickenpox** are highly contagious, systemic infections that gain entry through the respiratory system and cause rashes and fevers. Vaccines are available for all three. Measles is the most severe of the three and is responsible for significant mortality around the world. Chickenpox typically causes mild infections in children but the virus can reactivate to cause painful cases of **shingles** later in life.

22.4 Respiratory Mycoses

- Fungal pathogens rarely cause respiratory disease in healthy individuals, but inhalation of fungal spores can cause severe pneumonia and systemic infections in immunocompromised patients.

- Antifungal drugs like amphotericin B can control most fungal respiratory infections.
- **Histoplasmosis** is caused by a mold that grows in soil rich in bird or bat droppings. Few exposed individuals become sick, but vulnerable individuals are susceptible. The yeast-like infectious cells grow inside phagocytes.
- **Coccidioidomycosis** is also acquired from soil and, in some individuals, will cause lesions on the face. Extreme cases may infect other organs, causing death.
- **Blastomycosis**, a rare disease caused by a soil fungus, typically produces a mild lung infection but can become disseminated in the immunocompromised. Systemic cases are fatal if untreated.
- **Mucormycosis** is a rare disease, caused by fungi of the order Mucorales. It primarily affects immunocompromised people. Infection involves growth of the hyphae into infected tissues and can lead to death in some cases.
- **Aspergillosis**, caused by the common soil fungus *Aspergillus*, infects immunocompromised people. Hyphal balls may impede lung function and hyphal growth into tissues can cause damage. Disseminated forms can lead to death.
- **Pneumocystis pneumonia** is caused by the fungus *P. jirovecii*. The disease is found in patients with AIDS and other immunocompromised individuals. Sulfa drug treatments have side effects, but untreated cases may be fatal.
- **Cryptococcosis** is caused by *Cryptococcus neoformans*. Lung infections may move to the brain, causing meningitis, which can be fatal.

REVIEW QUESTIONS

Multiple Choice

1. Which of the following is not directly connected to the nasopharynx?
 - A. middle ear
 - B. oropharynx
 - C. lacrimal glands
 - D. nasal cavity
2. What type of cells produce the mucus for the mucous membranes?
 - A. goblet cells
 - B. macrophages
 - C. phagocytes
 - D. ciliated epithelial cells

3. Which of these correctly orders the structures through which air passes during inhalation?
 - A. pharynx → trachea → larynx → bronchi
 - B. pharynx → larynx → trachea → bronchi
 - C. larynx → pharynx → bronchi → trachea
 - D. larynx → pharynx → trachea → bronchi
4. The _____ separates the upper and lower respiratory tract.
 - A. bronchi
 - B. larynx
 - C. epiglottis
 - D. palatine tonsil
5. Which microbial virulence factor is most important for attachment to host respiratory tissues?
 - A. adhesins
 - B. lipopolysaccharide
 - C. hyaluronidase
 - D. capsules
6. Which of the following does not involve a bacterial exotoxin?
 - A. diphtheria
 - B. whooping cough
 - C. scarlet fever
 - D. Q fever
7. What disease is caused by *Coxiella burnetii*?
 - A. Q fever
 - B. tuberculosis
 - C. diphtheria
 - D. walking pneumonia
8. In which stage of pertussis is the characteristic whooping sound made?
 - A. convalescence
 - B. catarrhal
 - C. paroxysmal
 - D. prodromal
9. What is the causative agent of Q fever?
 - A. *Coxiella burnetii*
 - B. *Chlamydomphila psittaci*
 - C. *Mycoplasma pneumoniae*
 - D. *Streptococcus pyogenes*
10. Which of these microbes causes “walking pneumonia”?
 - A. *Klebsiella pneumoniae*
 - B. *Streptococcus pneumoniae*
 - C. *Mycoplasma pneumoniae*
 - D. *Chlamydomphila pneumoniae*
11. Which of the following viruses is not commonly associated with the common cold?
 - A. coronavirus
 - B. adenovirus
 - C. rhinovirus
 - D. varicella-zoster virus
12. Which of the following viral diseases has been eliminated from the general population worldwide?
 - A. smallpox
 - B. measles
 - C. German measles
 - D. influenza
13. What term refers to multinucleated cells that form when many host cells fuse together during infections?
 - A. Ghon elements
 - B. Reye syndrome
 - C. Koplik’s spots
 - D. syncytia
14. Which of the following diseases is not associated with coronavirus infections?
 - A. Middle East respiratory syndrome
 - B. German measles
 - C. the common cold
 - D. severe acute respiratory syndrome
15. Which of these viruses is responsible for causing shingles?
 - A. rubella virus
 - B. measles virus
 - C. varicella-zoster virus
 - D. variola major virus
16. Which of these infections is also referred to as Valley fever?
 - A. histoplasmosis
 - B. coccidioidomycosis
 - C. blastomycosis
 - D. aspergillosis
17. Which of the following is not caused by a dimorphic fungus?
 - A. histoplasmosis
 - B. coccidioidomycosis
 - C. blastomycosis
 - D. aspergillosis

18. Which of the following is caused by infections by bread molds?
- mucormycosis
 - coccidioidomycosis
 - cryptococcosis
 - Pneumocystis pneumonia*
19. In the United States, most histoplasmosis cases occur
- in the Pacific northwest.
 - in the desert southwest.
 - in the Mississippi river valley.
 - in Colorado river valley.
20. Which of the following infections can be diagnosed using a skin test similar to the tuberculin test?
- histoplasmosis
 - cryptococcosis
 - blastomycosis
 - aspergillosis

Fill in the Blank

21. Unattached microbes are moved from the lungs to the epiglottis by the _____ effect.
22. Many bacterial pathogens produce _____ to evade phagocytosis.
23. The main type of antibody in the mucous membrane defenses is _____.
24. _____ results from an inflammation of the “voice box.”
25. _____ phagocytize potential pathogens in the lower lung.
26. Calcified lesions called _____ form in the lungs of patients with TB.
27. An inflammation of the middle ear is called _____.
28. The _____ is used to serologically identify *Streptococcus pneumoniae* isolates.
29. _____ is a zoonotic infection that can be contracted by people who handle birds.
30. The main virulence factor involved in scarlet fever is the _____.
31. The _____ virus is responsible for causing German measles.
32. A(n) _____ is an uncontrolled positive feedback loop between cytokines and leucocytes.
33. In cases of shingles, the antiviral drug _____ may be prescribed.
34. The slow accumulation of genetic changes to an influenza virus over time is referred to as _____.
35. The _____ vaccine is effective in controlling both measles and rubella.
36. In coccidioidomycosis, _____ containing many endospores form in the lungs.
37. In cryptococcosis, the main fungal virulence factor is the _____, which helps the pathogen avoid phagocytosis.
38. In some mycoses, fungal balls called _____ form in the lungs
39. Most US cases of coccidioidomycosis occur in _____.
40. Coccidioidomycosis may develop when *Coccidioides immitis* _____ are inhaled.

Short Answer

41. Explain why the lower respiratory tract is essentially sterile.
42. Explain why pneumonia is often a life-threatening disease.
43. Name three bacteria that commonly cause pneumonia. Which is the most common cause?
44. How does smoking make an individual more susceptible to infections?
45. How does the diphtheria pathogen form a pseudomembrane?
46. Since we all have experienced many colds in our lifetime, why are we not resistant to future infections?
47. Which pulmonary fungal infection is most likely to be confused with tuberculosis? How can we discriminate between these two types of infection?
48. Compare and contrast aspergillosis and mucormycosis.

Critical Thinking

49. Name each of the structures of the respiratory tract shown, and state whether each has a relatively large or small normal microbiota.




Figure 22.30 (credit: modification of work by National Cancer Institute)

50. Cystic fibrosis causes, among other things, excess mucus to be formed in the lungs. The mucus is very dry and caked, unlike the moist, more-fluid mucus of normal lungs. What effect do you think that has on the lung's defenses?
51. Why do you think smokers are more likely to suffer from respiratory tract infections?
52. Why might β -lactam antibiotics be ineffective against *Mycoplasma pneumoniae* infections?
53. Why is proper antibiotic therapy especially important for patients with tuberculosis?
54. What role does the common cold have in the rise of antibiotic-resistant strains of bacteria in the United States?
55. Why is it highly unlikely that influenza A virus will ever be eradicated, like the smallpox virus?
56. Why are fungal pulmonary infections rarely transmissible from person to person?